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ABSTRACT 
 
Maternal physiology adapts throughout reproductive phases to meet the mineral needs of the 
fetuses and neonates. During pregnancy, intestinal calcium absorption doubles; conversely, 
during lactation, calcium is resorbed from the skeleton. Post-weaning, restoration of bone 
mineral content occurs, however the factors regulating these adaptations are unknown. Animals 
lacking the vitamin D receptor (VDR) or those deficient in vitamin D achieve post-weaning 
increases in bone mass, suggesting that calcitriol, the active form of vitamin D, is not required. 
An alternative explanation is that calcitriol may act through non-genomic receptors to have these 
effects. We used calcitriol-deficient Cyp27b1 null mice to test whether calcitriol is required for 
upregulation of intestinal calcium absorption and skeletal recovery post-weaning. Compared to 
WT, and despite a rescue diet containing 2 % calcium, at baseline Cyp27b1 nulls were 
hypocalcemic with markedly increased PTH and 30 % lower BMC; µCT displayed reduced 
femoral length, cortical thickness, and cortical area. During pregnancy serum calcium levels 
increased, PTH levels were reduced, and BMD increased by 45 %, so that all values became no 
different from WT. During lactation, serum calcium levels of Cyp27b1 nulls decreased, PTH 
levels increased, BMC declined more markedly than in WT, and bone strength decreased; µCT 
analysis confirmed extensive endocortical resorption. Post-weaning, serum calcium of Cyp27b1 
null normalized, PTH levels remained high, BMC increased, and bone strength recovered; µCT 
confirmed recovery of cortical parameters. In comparison to WT mice, the Cyp27b1 null females 
display very low levels of calcitriol throughout pregnancy and lactation. Intestinal calcium 
absorption is upregulated in the Cyp27b1 null mice during pregnancy. In conclusion, calcitriol-
independent mechanisms regulate mineral and bone metabolism during pregnancy and post-
weaning; however, absence of calcitriol leads to greater transient bone loss during lactation.  
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I. INTRODUCTION 
1.1 Adult mineral and bone homeostasis 
1.1.1 Purpose of the skeleton 
Mineral and bone metabolism in the adult is a tightly regulated process. Through the interaction 
of several physiological compartments and hormones, serum mineral homeostasis and skeletal 
strength are maintained. Preservation of the integrity of bone is particularly important, due to the 
organ’s numerous and essential roles in normal physiology to: provide internal support and 
protection for vital organs, enable locomotion through provision of attachment sites for muscles 
and tendons, host hematopoiesis in the bone marrow, and maintain a reservoir for inorganic ions, 
namely calcium and phosphate, for mobilization into circulation. 1 Bone also has a central role in 
mineral homeostasis through the flux of these minerals during formation and resorption. 
 
1.1.2 Target organs 
The main target organs involved in maintaining adult mineral and bone homeostasis include 
bone, the intestines, the parathyroid glands, and the kidneys. Blood serves as a form of 
communication among these organs. The constituents in blood, including the minerals and the 
hormones that are involved in regulating different target tissues, will first be described.  The role 
of each of the target organs will then be explained in greater detail followed by an illustration of 
how each of these components fit together. 
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1.1.3 Serum mineral concentrations 
1.1.3.1 Calcium 
The adult human is comprised of approximately 1000 g of calcium, distributed in various forms 
throughout the body. The majority of this mineral (99 %) exists as the hydroxyapatite crystal in 
the mineral phase of bone, and the remaining 1 % is located in blood, extracellular fluid, and soft 
tissues. 2 Of the total calcium in blood, 50 % is free or ionized, 40 % is bound to albumin, and 10 
% is bound to citrate or phosphate ions. 2 The free or ionized portion is biologically functional 
and is commonly used as an indicator of clinical calcium status. The normal range of 
extracellular ionized calcium is approximately 1.1-1.3 mM. 3 This level is tightly regulated 
because small decreases or increases disrupt the function of key organs and cells. Underlying this 
homeostasis is the Ca2+-sensing receptor (CaSR), which keeps the ionized calcium level 
constant. 3 The parathyroid glands, kidneys, intestine, C-cells of the thyroid gland, and 
osteoblasts, osteocytes, and osteoclasts in bone all express this receptor, however, the most 
important effect of altering serum calcium is a result of its function in the parathyroid glands. 3 
The typical human diet is either deficient or bordering on sufficient in calcium, so this 
mechanism is essential to ensure that the blood calcium stays within a narrow range. 
 
1.1.3.2 Phosphorus 
 Similar to calcium, phosphorus is one of the most abundant minerals in the human body and is 
maintained in strict homeostasis. In the adult human, approximately 600-700 g of phosphorus are 
stored with calcium as the hydroxyapatite constituent of bone, 100-200 g are distributed in soft 
tissues, and trace amounts are located in extracellular fluids. 4 There are two forms of phosphorus 
in extracellular fluids: the organic form of phospholipids and the inorganic form of phosphate.  4 
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The North American diet generally has much more phosphorus than needed; consequently we 
have to excrete the excess. There must be a phosphorus sensor, similar to the CaSR, however the 
phosphorus-sensing mechanism is poorly understood. Recently it has been suggested that inositol 
polyphosphate sensory domains are able to regulate phosphate intake, transport, and storage. 5  
 
1.1.4 Roles of the calcium and phosphorus-regulating hormones 
Maintaining the concentrations of calcium and phosphorus within the set ranges requires the 
interaction of several target organs and several hormones that communicate among them. These 
include: parathyroid hormone (PTH), calcitriol (1,25(OH)2D), fibroblast growth factor 23 
(FGF23), parathyroid hormone related peptide (PTHrP), and estradiol.  
 
1.1.4.1 Parathyroid hormone 
Parathyroid hormone (PTH) is initially synthesized in the parathyroid gland as its nascent form 
of a pre-pro-peptide consisting of 115 amino acids. 6 The mature PTH peptide consisting of 84 
amino acids is formed through removal of the pre- and pro-sequences. 7 This mature form is 
packaged into secretory vesicles within chief cells of the parathyroid gland from which it is 
secreted. 6 The main functions of PTH are to increase levels of serum calcium, lower serum 
phosphorus, stimulate production of calcitriol, and to control the degree to which the skeleton is 
forming or resorbing. The blood ionized calcium level is sensed by the CaSR at the plasma 
membrane of chief cells. 8 Calcium binds to the receptor, initiating signal transduction that leads 
to suppression of PTH secretion in the short term and reduced PTH mRNA transcription in the 
long term. 6 Conversely, a decline in extracellular calcium levels leads to reduced binding, 
disinhibition, and a rise in both PTH transcription and secretion. PTH then functions to restore 
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blood calcium levels to within the desired range of 1.1-1.3 mM through acting on bone, kidneys, 
and indirectly on the intestines.  
 
Within bone, the dominant action of PTH is on osteoblasts, as the PTH receptor is located within 
these cells. PTH stimulates osteoblasts to form bone. Intermittent elevation increases osteoblast 
number and bone formation by attenuating apoptosis and increasing osteoblast life span. 9 
However, if the stimulation of PTH is prolonged or of greater amplitude, then PTH causes bone 
resorption via the RANKL/OPG/RANK pathway (Figure 1). Specifically, PTH causes 
osteoblasts to make receptor activator nuclear factor-ĸB ligand (RANKL), which binds to RANK 
receptors on osteoclast precursor cells to promote their differentiation. 10 Simultaneously, PTH 
causes osteoblasts to reduce the expression of osteoprotegerin (OPG). 10 OPG acts as a “decoy” 
receptor for RANKL, such that a decrease leads to less competition and RANKL can bind more 
frequently to RANK. 11 The final result is that more osteoclasts are formed from precursors, 
recruited to the bone surface, and activated to resorb bone. 12  
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Figure 1: RANKL/OPG/RANK signalling pathway. 13 Osteoblasts make RANKL that binds to 
RANK on osteoclast precursor cells to promote their differefntiation. Osteoblasts and osteocytes 
also secrete OPG, a decoy receptor for RANKL that prevent binding of RANKL to RANK. 
Reprinted by permission from Macmillan Publishers Ltd: NATURE REVIEWS GENETICS, 
copyright 2012 (Appendix A). 
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PTH also plays a role in ensuring calcium balance through influencing renal function. PTH 
primarily stimulates renal calcium reabsorption in the proximal tubule and has a minor role in 
calcium excretion in the distal nephron. 2 Within the intestines, PTH has an indirect effect to 
maintain calcium balance that occurs via the kidneys, which will be discussed in section 1.1.6.  
 
In addition to its major role of regulating calcium balance, PTH also affects the balance of 
phosphorus. PTH increases renal phosphate excretion by suppressing the expression of sodium-
phosphate cotransporters NaPi2a and NaPi2c, thereby decreasing serum phosphate. 14 This will 
occur regardless of whether PTH is increased in response to low serum calcium or a high serum 
phosphate. A modest negative feedback loop is then evoked whereby low serum phosphate 
decreases PTH secretion and mRNA levels of PTH. 15,16 However, PTH is much more responsive 
to changes in calcium than it is to low phosphorus. 
 
A variety of other mechanisms serve to regulate the secretion of PTH. Diminished levels of 
calcitriol result in reduced intestinal calcium absorption, leading to a compensatory increase in 
PTH secretion. 6 The mechanism underlying this regulation involves liganded VDR binding to 
negative regulatory elements in the promoter region of the PTH gene. 17 A similar effect results 
from dietary calcium restriction independent of vitamin D or calcitriol. FGF23 also has an 
inhibitory role in the secretion of PTH, through phosphorylating ERK1/2 and activating the 
MAPK pathway.18 
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1.1.4.2 Vitamin D metabolism 
Calcitriol is the active form of vitamin D and has numerous biologically essential roles. It is 
synthesized from Vitamin D3 as taken in from the diet through fortified dairy products and fish 
oils, or in the skin from 7-dehydrocholesterol (7-DHC) by ultraviolet radiation. 19 The conversion 
from biologically inert Vitamin D3 to its active form involves two enzymatic modifications, first 
in the liver and then in the kidney (Figure 2). After D3 synthesis, the vitamin is transported in 
general circulation by the vitamin D binding protein (DBP). 20 This ferries vitamin D to fat and 
muscle for storage, and to the liver where the first conversion reaction occurs. Here, vitamin D3 
is hydroxylated by cytochrome P450 enzymes to the prohormone 25-hydroxyvitamin D3 
(25OHD). 19 The second modification then occurs after transport by DBP to the kidney, where 
25OHD is converted to 1,25-dihydroxyvitamin D3 (calcitriol) and 24,25-dihydroxyvitamin D3 
(24,25OHD). 19 CYP27B1 1α-hydroxylase (1αOH) is present predominantly in the kidney and 
metabolizes the first reaction to calcitriol. This enzyme is also present in extrarenal sites 
including the placenta, monocytes, and macrophages. 21,22 In either location, calcitriol binds to 
the vitamin D receptor (VDR) to conduct its actions. 19 In contrast, a catabolic pathway also 
exists that serves to lower calcitriol. The enzyme CYP24A (24OH) limits the amount of calcitriol 
in target tissues by converting 25OHD to 24,25OHD, and catabolizing calcidiol into 
1,24,25(OH)3D. 19 Both of these hydroxylated products are further degraded to water-soluble 
catabolites, although 24,25OHD and 1,24,25(OH)3D have their own limited biological activity.  
 
The entire process of vitamin D metabolism is tightly regulated, primarily at the level of the 
kidney (Figure 2). Substrate availability, amount of enzyme, cofactor availability, and enzymatic 
activity of CYP24A all control the action of 1αOH. 19 CYP24A is under stringent regulation by 
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calcitriol through negative feedback, as the enzyme can also hydroxylate calcitriol to form 
1,24,25(OH)3D and 1,25,OHD-26,23-lactone. Calcitriol may even be the preferred substrate for 
CYP24A. 23 Furthermore, numerous minerals and hormones also play a role in the metabolic 
pathway. PTH stimulates the production of calcitriol in the kidney, which in turn suppresses the 
production of PTH in a feedback loop. 19 PTH itself is suppressed by calcium via the CaSR, such 
that calcium has an inhibitory role in the production of calcitriol. Additionally, phosphate and 
FGF23 both inhibit calcitriol production. CYP24A is reciprocally regulated in contrast to 
CYP27B1, such that its activity is stimulated by phosphorus, calcium, calcitriol, and FGF23, and 
inhibited by PTH. 20 The dominant stimulator of CYP27B1 is normally PTH because in the 
absence of PTH, calcitriol is low. FGF23 however has an important negative influence because 
in the absence of FGF23, calcitriol levels are very high. Other hormones may also be involved, 
as calcitonin and prolactin have been reported to stimulate the production of calcitriol.24,25 
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Figure 2: Vitamin D Metabolism. 19 Vitamin D undergoes two enzymatic modifications before 
it becomes biologically active as calcitriol. The liver converts vitamin D to 25OHD, and the 
kidney converts 25OHD to 1,25(OH)2D (calcitriol) and 24,25OHD. Metabolic control is exerted 
primarily at the kidney. The action of 1αOH is controlled by substrate availability, amount of 
enzyme, cofactor availability, and enzymatic activity of CYP24A. Phosphate, calcium, and 
FGF23 also inhibit calcitriol production whereas PTH has a stimulatory effect. Copyright, John 
Wiley and Sons (Appendix B). 
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1.1.4.2.1 Calcitriol 
Calcitriol is biologically active and has numerous roles in affecting mineral metabolism. Its 
classical actions are on bone, the intestines, and the kidneys to regulate serum calcium and 
phosphorus. However, the actions of calcitriol may extend beyond the skeleton to include 
regulation of the immune system, such that it may inhibit growth of cancer cells and protect 
against immune mediated disorders.20 
 
The primary role of calcitriol is to stimulate intestinal calcium absorption. Calcitriol has been 
shown to stimulate both the active and passive pathways of calcium transport. 26 For the active 
pathway, calcitriol regulates the entire process, including entry of calcium across the brush 
border membrane, intracellular diffusion, and the energy requiring extrusion of calcium across 
the basolateral membrane. 19 In addition, calcitriol may also affect the rate of calcium intrusion 
and extrusion through the enterocyte, through stimulation of the plasma membrane calcium 
pump (PMCA). The actions of calcitriol may also be mediated by calbindin, the calcium binding 
protein, and TRPV6, a calcium selective channel. Intestinal phosphorus absorption is also 
stimulated by calcitriol, however the mechanism remains elusive.19 
 
Calcitriol also has formative effects within bone, however this is predominantly indirect. Animal 
models of disrupted vitamin D physiology including vitamin D-deficient rats27,28, vitamin D 
receptor knockout mice29, and Cyp27b1 knockout mice30,31 all have impaired intestinal calcium 
absorption, leading to secondary hyperparathyroidism and rickets after weaning. Bypassing the 
need for calcitriol or its receptor with oral or parenteral calcium results in normalization of both 
the PTH level and the skeleton. 31-34 Moreover, additional studies in the VDR null teased this role 
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out to a greater extent. Knockouts of the vitamin D receptor just from intestinal cells results in 
the same phenotype as the global VDR knockout, whereas knockout of the VDR from osteocytes, 
osteoblasts, or osteoclasts does not cause the VDR null bone phenotype. 35,36 Furthermore, 
expressing the VDR in intestinal cells in the global VDR knockout rescues the bone phenotype. 
35,37 These findings suggest that in regards to the skeleton, the main role of calcitriol is in 
delivery of mineral from upregulation of intestinal absorption. Any evidence supporting a direct 
role for calcitriol on bone cells is minimal. Double knockout models of both CYP27B1 and VDR 
fed a rescue diet have reduced bone volume, osteoblast number, and mineral apposition rate, 
indicating the skeletal phenotype was not completely prevented. 38  
 
The kidneys are also involved in calcitriol-mediated homeostasis. In the distal tubule, calcitriol 
enhances the actions of PTH on calcium transport through upregulation of the PTH receptor 
expression at both the mRNA and protein level. 39 Similar to the induction of calcium binding 
proteins and calcium selective channels in the intestine, calcitriol induces Calbindin-D28k and 
TRPV5 in the distal tubule, thus increasing calcium reabsorption and return to the circulation. 19 
A negative feedback loop exists to oppose this action, keeping calcium within a normal range. 
Through inhibiting CYP27B1 and inducing CYP24A, calcitriol moderates its own renal 
expression.40 
 
1.1.4.2.2 Vitamin D receptor 
Calcitriol is the hormonal ligand for the vitamin D receptor (VDR), which is to date the only 
known receptor for calcitriol. Belonging to a superfamily of nuclear receptors, VDR modulates 
gene expression through transcriptional regulation of target genes. Binding to DNA occurs as 
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heterodimers with the retinoid X receptor (RXR) on response elements within the gene. 41 The 
steroid hormone-binding domain is located from amino acid 182 to amino acid 427, providing 
high-affinity recognition. 42 The DNA-binding domain is a cysteine-rich region containing two 
zinc-fingers, and is located from amino acids 24-89. 42 Several coactivators are also involved in 
the transcriptional apparatus, such as SRC1, -2, and -3, and DRIP205. 43 Transcription factors 
YY1 and CCAAT, and SWI/SNF complexes that remodel chromatin additionally aid in the 
VDR-mediated transcription. 19 Once these proteins come together to form the complex, the 
DNA bends, serine-205 becomes phosphorylated, and the target gene is then activated or 
repressed (Figure 3). 43 The most powerfully regulated gene is the 24-hydroxylase enzyme that 
degrades vitamin D.44 
 
The vitamin D receptor is widely expressed throughout the body. In addition to its appearance in 
classical target tissues of osteoblasts, enterocytes, and distal renal tubule cells, VDR expression 
has been found in parathyroid gland cells, skin keratinocytes, promyelocytes, lymphocytes, colon 
cells, pituitary gland cells, and ovarian cells. 43 Its widespread expression in these tissues is what 
has led to the theory that calcitriol has many extraskeletal roles, most of which remain 
unproven.43 
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Figure 3: VDR modulation of gene expression by calcitriol. 43 VDR and its ligand form 
heterodimers with the retinoid X receptor (RXR) on VDR response elements (DRE) located in 
target genes. Together with co-activators and transcription factors, a complex forms that causes 
the DNA to bend. Phosphorylation occurs and transcription is either initiated or suppressed. 
Copyright, Am J Clin Nutr (2004;80:1692S), American Society for Nutrition (Appendix C). 
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1.1.4.3 Fibroblast growth factor 23 
Fibroblast growth factor 23 (FGF23) belongs to the family of FGFs that regulate numerous 
developmental processes. Specific to FGF23 is its high expression in bone, particularly in 
osteoblasts, osteocytes, bone-lining cells, and osteoprogenitor cells. 45 mRNA expression is also 
detectable in the thymus, brain, and heart. 46 The full-length protein is 32 kD, however cleavage 
products of 12 and 20kD are also secreted. 47 In contrast to the majority of other FGFs, FGF23 is 
an endocrine factor that requires both the FGF receptors and a co-receptor αKlotho for activity. 47 
The main function of FGF23 is to reduce serum phosphorus. This is achieved by reducing renal 
reabsorption through downregulation of the sodium-phophate cotransporters NAPI2a and 
NAPI2c, and by reducing intestinal absorption through suppression of NAPI2b. 48 The 
concentration of phosphate is then reciprocally regulated, as dietary intake of phosphate 
increases serum levels of FGF23. 49 In addition, FGF23 regulates calcitriol, such that high levels 
of calcitriol are measured in its absence. The inhibitory role of FGF23 is achieved through 
reducing expression of the anabolic enzyme CYP27B1 while increasing expression of the 
catabolic enzyme CYP24. 50 Thus, FGF23 has an indirect role in promoting a negative calcium 
balance by its actions to suppress intestinal calcium absorption. A negative feedback loop also 
exists with calcitriol, as injections of calcitriol result in increases of serum FGF23. 14 As calcitriol 
stimulates intestinal phosphorus absorption, FGF23 also has an indirect effect to lower serum 
phosphorus by reducing calcitriol. Lastly, FGF23 has a minor role in suppressing PTH. αKlotho 
is found in parathyroid cells where FGF23 inhibits PTH.18 
 
 
 
	   15	  
1.1.4.4 Parathyroid hormone related protein 
Parathyroid hormone related protein (PTHrP) is related to PTH, both derived from the same 
ancestral precursor through gene duplication. 51 They are structurally similar within the amino-
terminal end enabling them to bind and stimulate the same PTHR1 receptor. 51 Beyond the first 
13 amino acids however they share virtually no sequence homology. 52 PTHrP is normally absent 
from adult circulation apart from the progressive increase during pregnancy, coming from the 
placenta and breasts, and the more marked increase during lactation. Consequently PTHrP 
functions as a hormone in these time frames, but likely does not have endocrine function when it 
is undetectable. In the normal condition it is produced locally in certain tissues where it may 
have autocrine, paracrine, or intracrine functions. 53  
 
In humans, three different transcripts of the protein exist, containing 139, 141, or 173 amino 
acids. The physiological significance of these transcripts is uncertain, and in rodents, only the 
two shorter transcripts are found. 53 The physiological functions of PTHrP are diverse, as PTHrP 
mRNA has been found ubiquitously throughout body tissue. Some of the more well-documented 
local roles include that in the skeleton, smooth muscle, and mammary gland. In the skeleton, 
PTHrP stimulates growth of long bones during development through synchronizing chrondrocyte 
differentiation. 54,55 PTHrP is also critical in the cardiovascular system, as it functions to relax 
stretched smooth muscle cells in response to mechanical deformation, thus acting as a 
vasodilator. 53 In the mammary gland, the protein is important for branching morphogenesis.  
 
The hormonal roles of PTHrP during pregnancy and lactation are of even greater importance as 
they contribute to the regulation of mineral homeostasis. Similar to the role of PTH, PTHrP 
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contributes to increased bone turnover. The amino-terminal portions of PTHrP stimulate bone 
loss through upregulation of osteoclasts, whereas the carboxyterminal portions inhibit osteoclast-
mediated bone resorption. 55,56 PTHrP can also stimulate CYP27B1 but may be less potent than 
PTH. 51,57 Whether PTHrP accounts for the rise in calcitriol during pregnancy is uncertain. 56 The 
hormone has reciprocal roles in the kidneys, causing stimulation of calcium reabsorption but 
excretion of phosphorus. PTHrP is also particularly important for placental calcium transfer 
during pregnancy and regulating system calcium metabolism in the mammary gland during 
lactation.   
 
1.1.4.5 Estradiol 
Estradiol is the main circulating estrogen in premenopausal women. 58 It is synthesized in the 
ovaries from C19 metabolites of cholesterol. Estrogen receptor α (ERα) or β (ERβ) are 
transcriptionally activated by ligand binding with estradiol, and directly attach to estrogen 
response elements of target genes. 59 A nonclassical signaling pathway is also evoked by 
estradiol through activating cytoplasmic signaling cascades. 58 In this manner, the range of 
effects this hormone has on the body is vast and variable. Its main function is in the development 
and maintenance of female reproductive tissues, however estradiol also has profound effects on 
bone. Both ERα and ERβ have been detected in all skeletal cell types, with ERα having slightly 
higher expression. 60 Low levels of estradiol are responsible for linear bone growth, while higher 
levels drive the closure of the epiphyses and cease growth. 61 Additionally, estradiol affects 
skeletal maintenance through decreasing bone resorption, restraining the rate of bone 
remodeling, and assisting in maintaining a balance between bone formation and resorption. 58 
These antiresorptive properties result from inhibition of RANKL and promotion of OPG 
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expression by osteoblasts. When estradiol is low, such as the case with ovarian failure, then 
RANKL increases, OPG decreases, bone resorption increases, and net bone loss occurs. 56  
 
1.1.5 Role of the intestines 
Intestinal absorption of dietary calcium and phosphorus is crucial for maintaining skeletal 
homeostasis. For calcium, an average of 200 mg is absorbed per day. Two mechanisms are 
known to serve this purpose: a transcellular active transport process and a paracellular passive 
process. The active mechanism is located predominantly in the duodenum and upper jejunum 
and is regulated by calcitriol. 62 This route is responsible for a high proportion of calcium 
absorption when calcium intake is low, and in the growing young. 63 Movement across the 
absorptive enterocyte begins with entry through the calcium channel TRPV6, due to Ca2+ 
concentration differences between the intestinal lumen and cytosol. 64 The transport molecule 
calbindin9k then aids intracellular diffusion from the apical membrane to the basolateral 
membrane. 65 Here, extrusion of calcium is mediated by the Ca-ATPase. The sodium-calcium 
exchanger may also play a minor role in extrusion. However, studies on knockout mice of either 
TRPV6 or calbindin9k have shown increased intestinal calcium transport in response to in vivo 
administration of calcitriol, while double knockouts of both genes report impairments in 
absorption. 66,67 This suggests that the mechanisms explaining this route are still unclear, and that 
additional calcium channels or calbindins may also be involved in transport.  
 
Conversely, movement through the paracellular pathway occurs primarily when intake of 
calcium is normal or high, and increases relatively as the organism ages. 65 It is concentration-
dependent, non-saturable, and occurs at a rate inversely proportional to that of intestinal 
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propulsion. 68 Tight junctions regulate the epithelial permeability, which affects the paracellular 
flow of calcium ions. 65 This mechanism can be utilized in the absence of calcitriol by 
administering a diet high in calcium. However, despite functioning in its absence, this process 
can also driven by calcitriol. In a study by Fujita and colleagues, the tight junction proteins 
claudin-2 and claudin-12 were shown to form paracellar Ca2+ channels in intestinal mucosa, and 
that the expression of these proteins were upregulated both in vitro and in vivo by calcitriol.69 
 
For phosphorus, intestinal absorption also occurs via two mechanisms: one active, transcellular 
pathway, and one passive, paracellular pathway. The active pathway occurs mainly in the upper 
portion of the small intestine. 70 It requires a sodium-dependent phosphate transporter located at 
the apical membrane, NAPI2b that is regulated by calcitriol, the concentration of Pi in the 
intestinal lumen, and FGF23. 70 FGF23 controls this directly by suppressing NAPI2b, and 
indirectly by inhibiting calcitriol. The passive pathway is driven by electrochemical gradients 
and is usually sufficient to maintain homeostatic levels. 
 
1.1.6 Role of the kidneys 
The kidneys are responsible for calcium and phosphorus reabsorption and excretion, in addition 
to the formation of calcitriol. Maintaining a neutral balance of calcium involves eliminating 
approximately 200 mg per day, which is normally balanced by net intestinal calcium absorption. 
71 Both complexed and ionized calcium are filtered by the glomerulus in amounts exceeding 10 
g. 2 To balance these substantial amounts, approximately 98 % is reabsorbed along the nephron. 
The majority of this reabsorption (55 %) occurs along the proximal convoluted tubule. 
Approximately 10 % is then reabsorbed in the proximal straight tubule, 20 % in the loop of 
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Henle, 10 % in the proximal straight tubule, 10 % in the distal convoluted and connecting tubule, 
and 2 % in the collecting duct.71 
 
Calcium reabsorption can occur through either a paracellular, passive movement or a 
transcellular, active route. The passive mode of transport is driven by an electrical or chemical 
gradient and occurs largely in the proximal convoluted tubule and the proximal straight 
tubule.71Active transport begins with passive flux across the apical membrane, mediated by 
TRPV5 and TRPV6 channels. 72 Diffusion through the cytosol is then buffered by Calbindin-
D28K. Compartmentalization of Ca2+ in intracellular organelles is also important here to maintain 
the intracellular concentration within a narrow range. 71 Lastly, active extrusion across the 
basolateral membrane occurs via the plasma membrane Ca2+-dependent ATPase and the 
Na+/Ca2+ exchanger.71 
 
Multiple hormones influence calcium handling by the kidney. Both parathyroid hormone (PTH) 
and parathyroid hormone related peptide (PTHrP) increase the glomerular filtration rate and 
tubule reabsorption. 2 PTH stimulates CYP27b1 in the nephron, so that 25OHD is converted to 
calcitriol. This leads to an indirect action of PTH on the intestines for calcium absorption.2 
Calcitriol, estrogen, and dietary intake of calcium modulate the transcription of TRPV5 and 
TRPV6. 73 The trafficking and activity of these channels are stimulated by Klotho and 
calmodulin, respectively.73 
 
The kidneys are also responsible for maintaining a balance of phosphorus. Of the 7 g filtered by 
the kidneys per day, approximately 80-90 % is reabsorbed along the nephron with the remainder 
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being eliminated in urine. 74 Similar to calcium metabolism, the majority of phosphorus is 
reabsorbed along the proximal tubule.  74 Passive mechanisms are unable to account for the 
movement of phosphorus across the kidney. Rather, Na-Pi cotransport systems (NAPI) mediate 
active transport across the cell membrane. 75 PTH, FGF23 and calcitriol are involved in 
regulating this process. Parathyroid hormone inhibits phosphorus absorption in the renal 
proximal tubule and decreases Na-Pi cotransport at the apical membrane. 76 FGF23 also has an 
inhibitory role, reducing the activity of NAPI transporters in renal epithelial cells. 77 This means 
that PTH, PTHrP, and FGF23 cause phosphorus excretion. Conversely, calcitriol has a 
stimulatory role, increasing renal recovery of phosphorus.74 
 
The role of the kidneys in production of calcitriol is also critical for maintenance of mineral and 
bone homeostasis. The CYP27B1 1α-hydroxylase is predominantly located in this organ, and is 
thus the source of most of the calcitriol that becomes distributed throughout the body to exert its 
wide range of effects. 19 Cyp27b1 expression in other tissues does not contribute much to the 
circulating level as anephric patients have low calcitriol levels.78 
 
1.1.7 Role of bone 
Bone plays a critical role in mineral homeostasis through modulating the flux of minerals via 
resorption and formation. To understand how this is accomplished, it is important to explain the 
structure and composition of bone tissue.  
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1.1.7.1 Bone structure and composition 
Bone is a specialized form of connective tissue, containing cells, fibers, and ground substance. 79 
It is characterized morphologically as cancellous or cortical. Cancellous bone, otherwise known 
as trabecular bone, is composed of a meshwork of trabeculae. It is predominantly found at the 
epiphyseal region of long bones, but also in flat bones and vertebral bodies. 1 Its sponge-like 
construction allows for a reduction of skeletal weight without a compromise in strength. Further, 
it has a high metabolic rate and responds quickly to changes in mechanical loading. However, 
this also renders cancellous bone more susceptible to damage from bone loss. 1 Conversely, the 
architecture of cortical bone is thick and dense. This arrangement provides it with maximal load-
bearing capacity and strength, as a result of higher resistance to torsion and bending forces. 79 It 
is found largely at the diaphyses of long bones and accounts for 80 % of the weight of the human 
skeleton. Together, both forms contribute to overall bone strength.   
 
Three cell types comprise bone tissue: osteoblasts, osteocytes, and osteoclasts. Each of these 
cells serves distinct skeletal functions and intercommunicates through direct cell contact or 
signaling molecules. 80 Osteoblasts are differentiated from mesenchymal stem cells (MSCs) by 
the action of several transcription factors and signaling cascades.  Osteocytes are formed as a 
result of terminal differentiation of osteoblasts. Osteoclasts differentiate from the hematopoietic 
lineage and belong to the monocyte-macrophage family. Surrounding these cells lies the 
extracellular matrix (ECM), which makes up the preponderance of bone. In decreasing 
proportion, the ECM consists of mineral, collagen, water, noncollagenous proteins, and lipids. 81  
 
 
	   22	  
1.1.7.2 Osteoblasts 
Osteoblasts make up approximately 4-6 % of the human skeleton. 82 They are mononuclear cells 
that form tight junctions with adjacent osteoblasts. Extensions of their plasma membrane allow 
for communication between each other and the surrounding medium. As mentioned, osteoblasts 
are derived from MSCs by the action of a multitude of cytokines. 83 Each has a role in regulating 
the expression of cell-lineage specific sets of transcription factors. Runx2 is the master switch for 
osteoblast differentiation, binding to the promoter regions of the majority of osteoblast-specific 
genes including type 1 collagen (Col1), alkaline phosphatase (ALP), osteopontin (OPN), 
osteonectin (ON), and osteocalcin (OC). 84 Its importance to osteoblastogenesis is evidenced by 
Runx2 knockout mice who completely lack osteoblasts. 85 Further, Runx2 regulates the 
expression of the zinc-finger-containing transcription factor Osterix, which interacts with the 
Nuclear factor for activated T cells 2 (Nfatc2) to control the transcription of target osteoblastic 
genes. 86 Numerous other transcription factors are involved in osteoblast differentiation, 
including bone morphogenic proteins (BMPs), transforming growth factor ß (TGF- ß), WNTs, 
hedgehogs, parathyroid hormone (PTH), insulin-like growth factor-1 (IGF-1), fibroblast growth 
factors (FGFs), and Notch.83 
 
Primarily, osteoblasts function to synthesize the organic collagenous matrix and coordinate its 
mineralization. This process is maintained by the stages of differentiation: cellular proliferation, 
extracellular matrix deposition, matrix maturation, and mineralization. 87 Extracellular matrix 
components such as osteocalcin, osteopontin, and bone sialoprotein are initially deposited. 88 
Subsequently, mature osteoblasts mineralize the matrix to form new bone. 
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1.1.7.3 Osteoclasts 
Osteoclasts comprise the smallest percentage of bone cells, making up 1-2 % of the human 
skeleton. 82 They are large, multinucleated and highly motile, however they are usually seen 
apposed to the surface of bone. On the surface between the osteoclast and bone is an extensive 
ruffled border that consists of a series of finger-like cytoplasmic projections of the plasma 
membrane adjacent to bone. 89 Originating from hematopoietic stem cells, osteoclasts belong to 
the monocyte/macrophage family. 90 They are sufficiently developed in the presence of cytokine 
macrophage colony stimulating factor (M-CSF) and RANKL. 91 Respectively, these two ligands 
bind to the membrane receptors c-fms and RANK.   
 
The primary functions of osteoclasts are resorption and degradation of mineralized bone matrix. 
Imperative for the resorptive function is close contact between the osteoclast and underlying 
bone matrix, mediated by integrin αvß3. 91 This creates a microenvironment isolated from the 
extracellular space for the secretion of hydrochloric acid and proteolytic enzymes, which in turn 
break down bone into its component minerals and small proteinaceous fragments. The 
compartment is acidified to a pH of 4.5 by a vacuolar H+-ATPase and coupled chloride channel 
with a basolateral chloride-bicarbonate exchanger. 92 Resorption of bone is triggered by a 
polarization event. Acidified vesicles containing cathepsin K are transported via microtubules 
and actin to the sealing zone following osteoclastic bone recognition. 93 Attachment of these 
vesicles to the plasma membrane results in formation of the ruffled membrane containing the H+ 
machinery. Exocytosis of cathepsin K couples the release of H+ from this machinery, which 
functions to dissolve the matrix. 89 Type 1 collagen is degraded by cathepsin K, and its protein 
fragments are endocytosed into the surrounding intracellular fluid. 94 Release of the degradative 
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products may also be mediated by withdrawal of the osteoclast from the resorptive pit. A number 
of factors affect the secretion of acid and resulting bone resorption, including PTH and 
prostaglandin E2 that increase secretion, while calcitonin decreases secretion.95 
 
1.1.7.4 Osteocytes 
In the adult skeleton, osteocytes constitute over 90-95 % of all bone cells, and are regularly 
dispersed throughout the mineralized matrix. 82 They form an extensive lacunocanalicular 
network, with the cell body being encased in a lacuna and dendrites traveling through bone in 
canaliculi. 82 It has been estimated that there are approximately 42 billion osteocytes in the 
average adult human skeleton, with 3.7 trillion dendritic projections from these cells. 96 With 23 
trillion connections formed between these osteocytes and the cells on the bone surface, this order 
of magnitude is the same as current estimates of the neural network of the brain. 96 Osteocytes 
form as one of three possible destinies resulting from the terminal differentiation of an 
osteoprogenitor cell. By an unknown mechanism, some of these cells may also become lining 
cells or others may undergo apoptosis.97 
 
Rather than merely acting as a passive placeholder in bone, osteocytes have numerous integral 
functions. They act as orchestrators of bone remodeling, sending signals of resorption or 
formation in response to mechanical strain. The mechanical load placed on bones drives 
interstitial fluid to flow through the unmineralized matrix surrounding osteocytes and their 
dendritic processes. 98 As a result, osteocytes produce signaling molecules that regulate the 
activity of osteoclasts and osteoblasts. 99 Various biomolecules are responsible for this 
intercellular communication, including nitric oxide, prostaglandins, bone morphogenic proteins, 
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and Wnts. 100 Osteoblasts specifically can be stimulated by prostaglandins and Wnts, and 
inhibited by nitric oxide and sclerostin. Opposingly, formation and activity of osteoclasts can be 
stimulated by M-CSF and RANKL. 101  
 
Another mechanism by which osteocytes modulate bone remodeling is through their 
programmed cell death. Osteocyte apoptosis can occur at sites of microdamage, where 
proapoptotic molecules are increased. At these loci, apoptotic osteocytes release apoptotic bodies 
that express RANKL and recruit osteoclasts to resorb bone. 102 Microdamage can also cause a 
dendritic process to break, similarly recruiting osteoclasts to break down bone as part of the 
initiation of repair. The attraction of osteoclasts here is probably mediated by a combination of 
fluid pressure changes within the broken canaliculus as well as a release of factors from the fluid. 
Necrosis may also be a mechanism whereby osteocytes orchestrate bone resorption, as targeted 
ablation of osteocytes has been demonstrated to activate osteoclasts in mice. 103 Through a single 
injection of diptheria toxin in mice, 70 % of osteocytes were eliminated from cortical bone, and 
they exhibited fragile bone and trabecular bone loss consistent with osteoclast activation.  
 
Further research suggests that osteocytes can both add and remove mineral from its 
lacunocanalicular network. 104 Acting like osteoclasts, osteocytes can express genes of the 
hematopoietic lineage. This function is known as osteolytic osteolysis. Osteocytes can also act as 
osteoblasts, expressing genes of the mesenchymal lineage.  
 
Osteocytes can also function as an endocrine gland through regulation of phosphate homeostasis. 
104 Phex, Dmp1, and FGF23 are all highly expressed in osteocytes. As Phex and Dmp1 
	   26	  
downregulate the expression of FGF23, osteocytes can increase reabsorption of phosphate by the 
kidney. 105 This role is critical for maintaining sufficient circulating phosphate and the inherent 
bone mineral content. 
 
1.1.7.5 Bone remodeling 
Taking together the various components of bone, it is clear that the organ is not a static structure 
but rather highly dynamic. Bone undergoes consistent remodeling with 25 % of trabecular and 3 
% of cortical bone replaced each year. 106 This turnover is maintained by a delicate balance 
between osteoclast-mediated bone resorption and osteoblast-mediated bone formation. Such tight 
regulation is crucial for the repair of microdamages, replacement of old bone, and maintenance 
of calcium and phosphorus mobilization. 107 Any significant deviation from this balance could 
result in accelerated bone loss or bone gain. Therefore bone formation and bone resorption are 
normally coupled, such that increases to one results in increases to the other, or decreases to one 
causes decreases to the other. 107 This is accomplished by cross-communication between 
osteoblasts, osteoclasts, and osteocytes in a unique microenvironment known as a bone-
remodeling compartment (BRC). 1 The outer lining of the BRC is comprised of flattened cells, 
which secrete regulatory factors into the confined compartment space separated from the bone 
marrow. Avoiding interference from growth factors secreted by blood cells in the marrow 
facilitates local regulation of the remodeling process. 107 Generally, bone resorption is 
accomplished within 2-3 wks while bone formation requires a time period of 2-3 months. The 
cycle for remodeling may be initiated by signals from osteocytes that induce the activation of the 
quiescent bone surface, or by the action of hormones as a result of systemic changes in 
homeostasis. 1  
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1.1.8 Role of the parathyroid glands 
The parathyroid glands regulate the balance of serum minerals by responding to changes in 
calcium and phosphorus. They are the main source of parathyroid hormone, and are therefore 
responsible for its downstream effects to maintain the normocalcemic state. 6 In vivo, PTH is 
secreted in response to small decreases in blood ionized calcium levels, and functions to raise the 
blood level of calcium by promoting bone resorption, reabsorption of calcium by the kidneys, 
and intestinal calcium absorption. PTH also functions to lower the levels of serum phosphorus by 
increasing renal phosphate excretion. These functions are further explained in section 1.2.4.1. 
 
1.1.9 Interaction of target organs and the calciotropic and phosphotropic hormones  
Now that the target organs and dominant calcium and phosphorus-regulating hormones have 
been identified, it is possible to explain how these components interact with each other to 
maintain serum mineral concentrations and long-term skeletal strength and mineral content 
(Figure 4). Firstly, PTH and FGF23 antagonistically regulate calcitriol. Parathyroid hormone is 
the main stimulator of calcitriol synthesis, and is released in response to low levels of serum 
calcium and high levels of serum phosphorus; and inhibited by high levels of calcium. It also 
stimulates FGF23. Fibroblast growth factor 23 is also released in response to high levels of 
serum phosphorus and inhibits the production and enhances the catabolism of calcitriol. In turn, 
calcitriol suppresses PTH production by the parathyroid glands and stimulates FGF23 production 
in bone. Calcitriol also evokes a pathway of self-regulation through inhibiting its own synthesis, 
in addition to being inhibited by high levels of phosphorus and calcium. These feedback loops 
are key to the maintenance of bone and mineral homeostasis.  
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Further, the calciotropic and phosphotropic hormones also interact with the target organs.  The 
kidneys possess the CYP27B1 enzyme and are responsible for calcitriol synthesis. This 
conversion to the active form of vitamin D is modulated by the feedback loops previously 
mentioned, in addition to PTHrP that stimulates CYP27B1. The kidneys are also responsible for 
both mineral reabsorption and excretion. FGF23 and PTH reduce renal reabsorption of 
phosphate, while PTH stimulates renal reabsorption of calcium. The intestine is also a target 
organ in this complex interaction to regulate mineral homeostasis and bone metabolism. Its main 
function is calcium and phosphorus absorption, which is achieved through the action of 
calcitriol. The functions of bone are more extensive, with osteoblasts, osteoclasts, and osteocytes 
affecting the formation and resorption of bone, and creating a store of mineral and base. 
Estradiol and PTHrP exert their single function through acting on these bone cells, with estradiol 
inhibiting bone resorption and PTHrP promoting bone loss. Conversely, PTH and calcitriol can 
have both negative and positive effects on bone metabolism.  
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Figure 4: Interaction of the calcio/phosphotropic hormones and target organs in regulating 
bone and mineral homeostasis. Serum calcium and phosphorus are maintained within the 
desired range through the actions of PTH, calcitriol, FGF23, estradiol, and PTHrP on the 
parathyroid glands, kidneys, intestines, and bone. Feedback regulatory loops are also in operation 
to sustain the normal endocrinologic environment.   
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1.1.10 Human conditions of altered vitamin D metabolism 
The physiological importance of vitamin D is evident in human disorders where calcitriol is 
rendered absent or nonfunctional. This is the case in a nutritional vitamin D deficiency, or in 
genetic conditions of inactivation of the CYP27B1 gene or the VDR. Generally, these disorders 
cause impaired intestinal calcium and phosphorus absorption, which in turn causes insufficient 
mineralization of bone, leading to rickets in the growing child and osteomalacia in the adult. 
Rickets is characterized by decreased longitudinal growth, widening of the epiphyseal plate, and 
a bowing of tubular bones. 108 Children display slow developmental milestones in growth and 
walking. Osteomalacia is characterized by bone pain, muscular weakness, and difficulty walking. 
108 There is also increased propensity to fracture due to the low quantity of mineralized bone. In 
either condition, tetany and convulsions may also be present in concordance with low 
concentrations of serum calcium.  
 
1.1.10.1 Nutritional vitamin D deficiency  
Dietary deficiency of vitamin D can lead to rickets or osteomalacia as there is inadequate 
substrate to be metabolized to calcitriol. Although there is no current agreement on the threshold 
for adequate intake of vitamin D, it has been defined previously as the serum 25OHD that 
maximally suppresses PTH, as an arguable minimum level of serum 25OHD (15, 50-75, 40, or 
50 nmol/l), or as a recommended daily allowance of 600 IU/day for children and 800 IU/day for 
adults. 108 Several recent clinical trials in adults and children have shown that intestinal calcium 
absorption becomes maximal with a 25OHD level over 20 nmol/L, providing a strong argument 
for this as the threshold. 109-113 Certain populations are also more susceptible to vitamin D 
deficiency due to their age, latitude of habitat, skin color, type of clothing worn outdoors, 
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concomitant disorders, or drug usage. Children may be particularly vulnerable, as a result of 
insufficient levels of calcium in breast milk, or low sun exposure. 114 The elderly are also at 
increased risk, due to decreased dermal synthesis of vitamin D from UV-B irradiation. 108 
Cultural habits of non-western immigrants who migrate to countries at higher latitudes similarly 
place this population at risk for poor calcium absorption, such as avoiding sunlight and wearing 
clothes that cover most of the skin, which may be compounded by a diet low in calcium. 108 
Conditions of malabsorption also increase the likelihood of a vitamin D deficiency, including 
celiac disease, Crohn’s disease, gastrectomy, gastric bypass, bowel resection, or pancreatitis. 
Lastly, certain drugs may have rachitic side effects, such as anticonvulsant therapy that increases 
the catabolism of calcitriol. 108 Treatment of this deficiency is largely met by a prescribed dose of 
vitamin D3 and a calcium supplement. 
 
1.1.10.2 Vitamin D-dependent rickets type 1 
Inherited abnormalities of the Cyp27b1 gene can also lead to rickets and osteomalacia as a result 
of altered vitamin D metabolism. In this condition, the conversion of 25OHD to calcitriol is 
prevented due to a deficit in the 1αOH enzyme. 115 Inheritance follows an autosomal recessive 
mode of transmission. 116 The Cyp27b1 gene was mapped to chromosome 12q13.3, and several 
homozygous mutations have since been reported. Examples of these inactivating mutations 
include: Arg107His, Gly125Glu, Arg335Pro, and Pro382Ser. 115 The phenotype is 
heterogeneous, with symptoms ranging from hypotonia, weakness, growth failure, hypocalcemia, 
seizures, elevated PTH, and aminoaciduria. 115 Despite supplementation with vitamin D, patients 
retain low serum concentrations of calcitriol. 116 Treatment requires physiologic doses of 
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calcitriol or 1α-hydroxyvitamin D; a marketed form of vitamin D that gets hydroxylated in the 
liver to become calcitriol. 
 
1.1.10.3 Vitamin D-dependent rickets type 2 
Another rare genetic condition leading to rickets and osteomalacia is caused by inactivating 
mutations of the vitamin D receptor. In this condition, calcitriol is rendered nonfunctional due to 
resistance of target organs to the action of the active hormone. These inborn errors are also 
inherited in an autosomal recessive manner. 108 Mutations have been identified at both domains 
of the VDR. In the calcitriol-binding domain, a nonsense mutation was identified at nucleotide 
970, changing tyrosine to a premature stop codon. 117 In the DNA-binding domain, missense 
mutations within exons 2 and 3 have been reported, which are responsible for encoding the zinc-
finger structures. 42 These include a p.Gly30Asp mutation and a p.Arg70Gln mutation, both of 
which affect highly conserved amino acids essential for the function of DNA-binding. 42 
Symptoms include severe rickets, seizures, hypocalcemia, secondary hyperparathyroidism, and 
scalp and body alopecia. 42 Further, these patients have very high serum levels of calcitriol. 118 
Despite supplementation with calcitriol, rachitic symptoms remain. Treatment is not always 
effective and depends on the degree of hypocalcemia. If there is only limited hormone resistance, 
treatment with pharmacologic doses of calcitriol can upregulate calcium absorption and heal the 
symptoms of rickets. 108 If, however, there is complete abolishment of VDR function, no amount 
of calcitriol will have an effect, and so infusions of calcium and high oral doses are needed to 
overcome defective absorption of the mineral.108 
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1.1.11 Animal models of altered vitamin D metabolism 
In addition to the human data on conditions of defective vitamin D metabolism, several animal 
models have been investigated. These are particularly useful for reproductive research as their 
gestational time is significantly shorter (~3 wks as compared to 9 months in humans). The 
animal models studied to date include vitamin D deficient rats, vitamin D deficient mice, VDR 
null mice, Cyp27b1 null pigs and Cyp27b1 null mice.  
 
1.1.11.1 Vitamin D deficient rats  
Multiple studies have investigated severely vitamin D deficient rats. 28,119-121 These animals were 
obtained as weanlings from a colony maintained on a diet that lacked vitamin D but contained 
0.47 % calcium and 0.3 % phosphorus. 27 No exposure to UV light was permitted. At birth, the 
pups had normal skeletal lengths, morphology, ash weight, and mineral content of the ash. It is 
not until weaning that the pups begin to develop hypocalcemia, reduced mineralization, and 
rickets. These findings suggest that vitamin D is not required during fetal development to 
regulate calcium homeostasis, skeletal growth or mineralization. However, vitamin D becomes 
required at the time of weaning, when delivery of minerals is achieved through the intestines. 122  
 
1.1.11.2 Vitamin D deficient mice 
Vitamin D deficient mice from two different genetic backgrounds have been studied in recent 
years. CD1 mice (outbred swiss mice from Charles River) were maintained on a diet containing 
1.2 % calcium and 0.5 % phosphorus.  Similar to the vitamin D deficient rats, they had normal 
concentrations of serum calcium and ionized calcium at birth. 123 Mice from the Swiss 
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background were also studied, however they had 20 % lower calcium levels than vitamin D-
replete mice and normal phosphorus. 124  
 
1.1.11.3 VDR null mice  
Three different models of Vdr null mice have been studied; one developed in Boston, the second 
by a group in Leuven, and the third by a group in Tokyo. The Boston model (VdrBos) was 
engineered into C57BL/6 mice and has a deletion of the second zinc finger of the VDR DNA-
binding domain resulting in no translated product. 29 Conversely, both the Leuven model (VdrLeu) 
and Tokyo model (VdrTok) were engineered into CD1 mice and have a deleted exon encoding the 
first zinc finger of the VDR, such that a splice variant is secreted with normal ligand binding 
ability but no DNA binding ability. 122,125,126 VdrLeu and VdrTok mice were backcrossed to 
C57BL/6 and showed no phenotypical differences at birth between null and WT fetuses. 126,127 
Specifically, studies on VdrLeu mice showed normal serum calcium, phosphorus, PTH, renal 
excretion of calcium and phosphorus, and skeletal mineralization; and VdrTok mice were 
described as having normal growth rate and behaviour. VdrBos mice were backcrossed to Black 
Swiss and also had fetuses with normal serum mineral concentrations in addition to normal 
skeletal development. 128 It is upon weaning through early adulthood that the animals of all three 
models become afflicted by hypocalcemia, secondary hyperparathyroidism, hypophosphatemia, 
and rickets when on a standard chow (1 % calcium, 0.75 % phosphorus). It is at this time when 
the intestines become more dependent on active, calcitriol-dependent intestinal calcium 
absorption. However, use of a rescue diet allows for normal serum chemistries, skeletal 
morphology, and skeletal mineral content, bypassing the need for the VDR. 122 
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1.1.11.4 Cyp27b1 null pigs 
Pigs unable to synthesize calcitriol were acquired from the “Hannover Pig Strain”, which suffers 
from a naturally occurring null mutation of the 1α-hydroxylase. 129 The disease is inherited in an 
autosomal recessive manner. In the uterus, serum minerals are all normal. Symptoms present 
between four to six wks of age and closely resemble that of humans with vitamin D-dependent 
rickets type 1. Sows display a rachitic phenotype with hypocalcemia, hypophosphatemia, and -
unphyiosological low concentrations of calcitriol in plasma, matching the human condition. 
 
1.1.11.5 Cyp27b1 null mice 
The Cyp27b1 gene consists of nine functional protein-coding exons, and two different models of 
Cyp27b1 null mice have been studied (Figure 5). Dardenne and colleagues first engineered the 
model in 2001, inactivating the enzyme by deleting exon 8 encoding the heme binding domain, 
and part of introns 7 and 8. 30 That same year Panda and colleagues engineered a similar model, 
fully ablating the enzyme by deleting both the hormone binding domain encoded by exons 6 and 
7, and the heme binding domain encoded by exon 8. 31 As with the previous animal models of 
defective vitamin D metabolism, Cyp27b1 null mice are phenotypically normal at birth through 
most of the suckling period. At weaning, they have hypocalcemia that worsens with age, in 
addition to hypomineralization of bones and rickets. In response to the decreased blood calcium 
levels, the knockout mice have increased blood PTH levels, and this secondary 
hyperparathyroidism also becomes more pronounced with age. Further, as mediated by the low 
levels of extracellular calcium and phosphorus, the mice develop uterine hypoplasia and 
infertility when on a standard laboratory diet (1% calcium).  
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Figure 5: The Cyp27b1 gene. Schematic representation of the 1αOH and the two mutant alleles 
studied to date. The WT allele is comprised of 9 exons, of which exons 6 and 7 encode the 
hormone binding domain while exon 8 encodes the heme binding domain. Dardenne inactivated 
the enzyme by cre-mediated excision of exon 8. Panda inactivated the enzyme by homologous 
recombination with a neomyocin resistance cassette replacing exons 6, 7, and 8. 
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Both models were later studied on a rescue diet of high calcium, high phosphorus, and high 
lactose at weaning. All groups claim that the diet rescued the phenotype of pseudo vitamin D 
deficiency rickets. In the first model by Dardenne and colleagues, mice were placed on this diet 
from 3 wks of age until harvest at 8.5 wks of age, at which point serum analyses, bone histology, 
histomorphometry, and biomechanical analysis were performed. 33 The high calcium diet 
corrected hypocalcemia and secondary hyperparathyroidism, and histomorphometry confirmed 
that rickets and osteomalacia was cured. The only difference the authors noted between 
genotypes was that the null mice gained weight less rapidly and that femur size remained 
smaller. The second model was also studied on the rescue diet at 3 wks of age until 15 wks, first 
by the original authors and then by Sun and colleagues. 38,130 Panda found that serum calcium, 
phosphorus, and PTH normalized to WT, in line with the initial paper stating that the rachitic 
phenotype was cured on the diet. However, they found several skeletal alterations in contrast to 
normal, including decreased femoral size, enlargement and distortion of the growth plate, 
reduced trabecular bone volume, reduced osteoid volume, and reduced osteoblast number. Panda 
and colleagues suggest that the observed skeletal abnormalities may be due to prolonged 
exposure to the rescue diet post-weaning and that bone formation may be more dependent on 
vitamin D as the animals age. The results by Sun and colleagues were again similar to previous 
findings indicating a reversal of rickets, as they observed normalization in both serum calcium 
and serum phosphorus at 3 months of age.  In addition, they found a reversal in the defective 
reproductive phenotype.  
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1.2 Adaptations during pregnancy and the role of calcitriol 
Mineral and bone metabolism is significantly challenged during pregnancy due to the incredible 
demand from the developing fetus and placenta. A full-term fetus requires sufficient mineral to 
be provided throughout pregnancy, 80 % of which is accreted during the third trimester in 
humans. 131 For calcium, an average of 30 g is accumulated by birth. 132 For phosphorus and 
magnesium, 20 g and 0.80 g are obtained by term, respectively. 133 The proportional demand for 
mineral is even greater in rodents, due to their shorter gestational period and larger litter size. A 
mouse delivers more than 95 % of the mineral content to their fetuses within the last 5 days of 
pregnancy. 56  
 
A plethora of changes in calciotropic hormone levels occur during this time period as compared 
to the normal adult state (Table 1). During normal human pregnancy, serum phosphate and 
magnesium remain constant, while serum calcium decreases as the fetus grows. 134 Calcium in 
serum is bound principally to albumin, so the observed declines during pregnancy generally 
represent the reductions in the albumin-bound fraction and is therefore physiologically 
unimportant. Measurements of ionized calcium indicate that the pre-pregnancy level is 
maintained throughout gestation, confirming that there is no real change in the physiologically 
relevant level of calcium in the blood. 134 In contrast, PTH experiences a significant decrease 
during the first trimester, then a recovery to its normal value by term. 135 Calcitriol, although 
stimulated by parathyroid hormone, has relative excursions distinct from PTH. Total calcitriol 
levels double or triple early in pregnancy and maintain this increase until term. 56 Levels of free 
calcitriol are increased in all three trimesters, as indicated by a modest increase in vitamin D 
binding protein and a decline in serum albumin. 56 To modulate this increase, the maternal kidney 
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1α-hydroxylase is upregulated, as a result of hormonal stimulators such as estradiol, prolactin, 
and placental lactogen. 136 PTHrP levels are also increased in the circulation during pregnancy 
due to multiple tissues in the mother and the fetus, and may contribute to the stimulation of 
calcitriol synthesis. 136 In addition, PTHrP may also suppress PTH during this time. The mineral 
physiology of rodent pregnancy is largely similar to that of human pregnancy, however rats have 
low ionized calcium and increased PTH concentration. The increase of serum calcitriol levels in 
mice and rats may also be greater than that measured in humans, with measurements of two to 
seven-fold increases.56 
 
Table 1: Changes in serum concentrations of humans and rodents during pregnancy 
compared to the non-pregnant, non-lactating mature female 
 Human 56 Rat 56 Mouse 56 
Serum calcium Low Low Normal 
Ionized calcium Normal Low Normal 
Phosphorus Normal Normal Normal 
Magnesium Normal Normal Normal 
PTH Low or low-normal Increased Low or normal 
Calcitriol Increased Increased Increased 
PTHrP Increased Increased Increased 
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The source of the increased concentrations of calcitriol during pregnancy has been a cause of 
debate, whether it is due to contribution from the placenta or maternal kidneys. Previous studies 
have indicated that in vitro, cultures of both full-term and young (8-12 wks gestation) placental 
tissue express Cyp27b1 and synthesize calcitriol. 21 Rats that have had 5/6 of their kidneys 
removed had a relatively normal increase in calcitriol during pregnancy. 137 The authors 
concluded that the pregnancy-induced increase in calcitriol could only be due to the placenta; 
however, the result is still compatible with the remaining kidney increasing calcitriol production. 
This is made more evident by studies in completely nephrectomized rodents, which had a greatly 
reduced amount of tritiated calcitriol in the maternal circulation after tritiated 25OHD was 
administered to the fetuses. 138,139 Whether that calcitriol was synthesized in the placenta or other 
maternal tissues is unclear. Additionally, maternal renal Cyp27b1 mRNA expression is 35-fold 
higher than placental Cyp27b1 expression. 140 Human data are compatible with the maternal 
kidneys and not the placenta being the dominant source of calcitriol in the maternal circulation 
because anephric women do not have higher amounts of calcitriol in the circulation during 
pregnancy. 78 Thus, the data are most consistent with the role of the kidney being more important 
for pregnancy-stimulated calcitriol than the placenta.  
 
To meet the need for calcium delivery, the mother relies primarily on increased efficiency of 
intestinal absorption, with minor contributions from skeletal mineral. Intestinal calcium 
absorption is doubled from as early as 12 wks gestation in humans, whereas in rats does not 
double until day 20-22 of their 24 day gestation. 56,141 The extent of resorption that occurs during 
this time however is less certain. Skeletal resorption can certainly be marked when dietary intake 
is insufficient to meet the combination of maternal and fetal demand for this mineral. Human 
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data indicate that a positive calcium balance occurs by mid pregnancy, though there is a lack of 
data on bone mass, structure, and mineralization at this time point. Markers of bone formation 
and resorption are both low in the first trimester and increase by term, suggesting that bone 
turnover may be increased in the third trimester. 141 This pattern is consistent with a demand for 
mineral late in pregnancy and the resulting need to resorb from the maternal skeleton. Most dual 
x-ray absorptiometry (DXA) studies have only been done before and after pregnancy to avoid 
fetal radiation exposure, thus any information on bone mineral content during pregnancy is 
limited. Generally these small studies show 0 % to 5 % decreases in lumbar spine BMC from 1-8 
months before pregnancy to 1-6 wks after delivery. 142-144 One large study found BMD to be 
reduced by 1.8 % at the lumbar spine, 3.2 % at the total hip, and 2.4 % at the whole body from 
baseline to 15 days postpartum. 145 It is unclear whether these small changes are due to 
pregnancy or bone loss from the onset of breastfeeding. Another study measured DXA of the 
radius during pregnancy, and found no change across the three trimesters. 146 Overall the results 
suggest that BMC declines minimally or has no change as a result of upregulated bone 
resorption. Bone loss may be more likely to occur in women who do not meet the calcium 
absorption requirements for themselves and their fetus.  
 
Animal models may be better suited than humans to estimating the changes in BMC during 
pregnancy as measurements can be assessed throughout gestation. In mice, bone mineral content 
(BMC) may increase or decrease depending on the genetic background and skeletal site. 134 
Outbred mice of the Black Swiss strain have a progressive 10-20 % increase in whole body 
BMC, no change in lumbar spine, and a 10-15 % gain in hind limb. 140,147,148 C57BL/6 mice show 
a 5 % decrease in whole body, a 15 % decline in lumbar spine, and a 10-20 % gain in the hind 
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limb BMC. 149 Conversely, CD1 mice show no significant changes in BMC at any region. 150 In 
rats, histomorphometric parameters of both bone formation and bone resorption are increased, 
however, bone mass remains constant. 134 This assessment is complicated by only comparing pre-
pregnancy to end of pregnancy, such that increases in bone mass early in pregnancy followed by 
bone resorption later on would not be measured.  
 
Pregnancy also leads to physiological changes in kidney function. Both human and animal data 
show an increase in creatinine clearance and glomular filtration rate (GFR). 134 From wk 12 of 
human gestation, the 24-hr urine calcium excretion is increased, largely due to increased 
intestinal absorption of calcium. 134 When participants are fasted however, these values remain 
normal or low.  
 
It is unclear how big of a role calcitriol plays during pregnancy. Supporting a major role for the 
hormone is its function in stimulating intestinal calcium absorption and deposition of mineral to 
the skeleton through increasing calcium channels TRPV5/6, transport molecule calbindin9k, 
Ca2+-ATPase and the sodium-calcium exchanger. 56 Concentrations of calcitriol increase two to 
three-fold in human pregnancy and two to seven-fold in rodent pregnancy. However, human and 
animal data are also compatible with calcitriol not being the main stimulator during pregnancy. 
Previous human studies have indicated that intestinal calcium absorption increases in the first 
trimester while calcitriol does not markedly increase until the third trimester. 141 This could 
suggest that calcitriol is not required for early upregulation of intestinal calcium absorption, but 
more for the peak demand later in pregnancy. Studies in severely vitamin D-deficient 
rats27,120,151,152, Cyp27b1 null pigs129,153, and VDR null mice147,154 also suggest that calcitriol is 
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not required to invoke the adaptations of pregnancy or that other hormones may be able to 
compensate when calcitriol is absent. Vitamin D deficient rats demonstrate an increase in 
calcium transport in the intestine, and mice lacking the vitamin D receptor also demonstrate 
increased duodenal calcium absorption. 120,147,155 Severely vitamin D deficient rats have shown 
both increases and decreases in bone mineralization during pregnancy. 152,156 VDR null mice 
undergo increases of 55 % in bone mineral content (BMC) as measured by DXA, in addition to 
having a marked reduction in secondary hyperparathyroidism, normalized serum calcium, and 
increased renal calcium excretion. 147 Another study of VDR nulls demonstrate increased serum 
calcium, an increase in trabecular BMD of the femur, increased femoral ash weight, and reduced 
osteoid and osteoclast paramaters as assessed by histomorphometry. 157 It was noted that both of 
the VDR studies used a calcium-enriched diet at the time of mating to restore fertility. Although 
this may have partially confounded the results to increase bone mass and modulate the 
improvements to mineral homeostasis, the enriched diet was found to not completely account for 
the full increase in BMC during pregnancy. 147 Collectively this suggests that vitamin D, 
calcitriol, or its receptor is not required for normal intestinal and skeletal adaptations of 
reproduction. In its absence, additional factors such as prolactin, placental lactatogen, estradiol, 
or calcitonin may be partially compensating. 158-165  
 
1.3 Adaptations during lactation and the role of calcitriol 
Lactation is similarly characterized by significant calcium demand and numerous adaptations to 
the normal adult state. During nine months of breastfeeding, 30 g of calcium is transferred from 
the mother to the neonate. 166 Per day, the average calcium loss into milk is 200-210 mg. 167 In 
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rodents, maternal milk output increases proportionally with number of pups in the litter and their 
weight.56 
 
Calcium, phosphorus, and the calciotropic hormones adapt to the increased calcium demands of 
the lactating mother (Table 2). In humans, serum calcium is unchanged or slightly increased. 168 
Similarly, ionized calcium levels are normal or somewhat increased. Measurements of serum 
phosphate indicate that levels are increased, due to increased renal phosphate absorption and 
skeletal resorption of the mineral. 141 Parathyroid hormone levels are decreased by 50 % during 
breastfeeding, as measured by intact PTH assays. This level rises to normal by weaning. 
Calcitriol levels of lactating women decrease from pregnancy to normal levels. PTHrP levels are 
also significantly increased during this time, with expression upregulated in lactating mammary 
tissue. 141 Lastly, estradiol levels decrease as a result of delivering the placenta and from high 
prolactin levels suppressing ovarian function. 56 Despite similarities to human lactation, there are 
several key differences within the mineral physiology of rodents during this time. In rats, the 
levels of both serum calcium and ionized calcium are largely variable, with animals measured to 
be hypocalcemic, normocalcemic, and hypercalcemic, due to differences in strains, litter sizes, 
and diet. 56 Specifically, rodents will become hypocalcemic with larger litter sizes or reduced 
calcium content of the diet. Measurements of serum phosphorus are also variable in both rats and 
mice. Another major difference is in the levels of calcitriol, where the 2-fold increase seen in 
pregnancy is also observed during lactation. 169 Estradiol is likely suppressed in rodents but this 
is unclear due to the sensitivity of available assays.   
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Table 2: Changes in serum concentrations of humans and rodents during lactation 
compared to the non-pregnant, non-lactating mature female 
 Human 56 Rat 56 Mouse 56 
Serum calcium Normal Variable Normal 
Ionized calcium Normal to slightly increased Low  Normal 
Phosphorus Increased Variable Variable 
PTH Low Increased Low to normal 
Calcitriol Normal Increased Increased 
PTHrP Increased Increased Increased 
Estradiol Low Low? Low? 
 
 
In contrast to the main adaptation of increased intestinal calcium absorption during pregnancy, 
intestinal calcium absorption is normal during lactation in women as compared to the non-
pregnant, non-lactating mature female. Calcium demand is largely met by an increase in bone 
resorption with moderate contribution from renal conservation of calcium. 141 Rodents however 
have a greater calcium demand due to their larger litter sizes and shorter duration of time 
lactating (21 days). So in addition to the skeletal and renal contributions, they also maintain an 
increased rate of intestinal calcium absorption, similar to what was achieved during pregnancy.  
 
Mobilization of skeletal calcium is a result of increased trabecular bone resorption by osteoclasts 
and mineral resorption in both trabecular and cortical bone by osteolytic osteolysis. 56 As a result, 
there are drastic changes to skeletal microarchitecture and strength. Histomorphometric studies 
reveal increases in osteoblast number, osteoblast surface, and osteoid thickness, and even greater 
increases in osteoclast number and resorptive surfaces. 56 This leads to reduced mineralized 
tissue volumes, thinning of trabeculae, and decreased trabecular number. Furthermore, osteocyte 
lacunae are enlarged, leading to objective loss of bone. The strength, stiffness, and toughness of 
vertebrae, tibia, and femora are all adversely affected by these changes to the skeleton. Hormonal 
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regulators of these adaptations include upregulation of PTHrP and low estradiol levels. In 
humans, losses of 3-10 % have been measured at trabecular sites, with smaller losses at cortical 
sites from the 2-6 months of lactation. 170 Despite any supplemental calcium intake, this negative 
calcium balance remains while breastfeeding. 171 Multiple randomized trials comparing 1,800 mg 
to 800 mg calcium intake, 2,400 mg to 1,200 mg, 1,400 mg to <300 mg and a 1 g supplement to 
controls demonstrated that BMC declined to the same extent in both groups. 172-175 Relative 
losses in 3 months or 6 months of lactation were also not affected by maternal calcium intake. 
176,177 It is noted however that prolonging the period of breastfeeding results in even greater bone 
loss. 178 These results all show that in humans, increasing calcium intake above the recommended 
daily amount does not reduce the amount of BMC lost during lactation. Conversely, bone loss in 
rodents is suppressible by a high calcium diet. In the C57BL/6 strain of mice, losses of 25% or 
more from the lumbar spine during the three wks of lactation are normal. 149 The effect of diet is 
shown when lactating mice fed a 2 % calcium diet had blunted BMC losses in comparison to 
mice fed a 1 % calcium diet. 140 However, bone loss was still not prevented. Taken together with 
the human data, these results confirm that bone loss during lactation is hormonally dependent 
rather than simply a function of diet. 
 
As mentioned, rodents maintain an increased rate of intestinal calcium absorption during 
lactation that is accompanied by an increase in calcitriol, while both levels fall in humans. Rats, 
and likely mice, upregulate duodenal expression of calbindin9k, Ca-ATPase, and VDR to 
moderate this adaptation. 56 The kidneys also participate in the adaptations to provide milk to the 
neonate in both humans and rodents, as this period is characterized by a reduction in GFR. Urine 
calcium excretion has been measured as low as 50 mg over a time period of 24 hrs. 141 The 
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reduction in urine calcium excretion, accompanied by increased urine phosphorus excretion, is 
consistent with the actions of PTHrP on kidney tubules and thereby implies that PTHrP is likely 
responsible for these changes in urine mineral handling. 56  
 
Prior animal models provide insight into the role of calcitriol during lactation. It is again unclear 
how big of a role calcitriol plays, as the hormone acts both directly and indirectly to promote 
deposition of skeletal mineral, however bone loss is similar despite absence of VDR or vitamin 
D deficiency. VDR null mice raised on a standard 1 % calcium diet and switched to a 2 % 
calcium diet prior to mating resorbed their skeleton normally during lactation as compared to 
their WT sisters. 147 Additionally, serum calcium and phosphorus remained normal throughout 
this time. The same VDR null mice were also studied on a 2 % calcium diet since the time of 
weaning so as to prevent acquisition of the rachitic phenotype. 179 During lactation, the knockout 
mice resorbed a similar amount of bone as measured by microCT and ash weight, and lost a 
similar amount of femoral bone strength. This suggests that the resorption of bone occurs 
independently of the vitamin D receptor. Vitamin D-deficient mice from the CD1 background 
also had normal serum calcium and ionized calcium during lactation, in addition to normal 
nutritional and calcium content in their milk. 123 Only moderate differences in these mice were 
noted, with lower serum phosphorus and 15 % lower lactose content in their milk. Vitamin D-
deficient mice in the NIH Swiss background had opposing results, with mild hypocalcemia but 
normal phosphorus compared to vitamin D-replete mice. 124 Studies in vitamin D-deficient rats 
are slightly different, as they were more likely to become hypocalcemic during lactation 
regardless of the calcium content of their diet. 152,155,156,180-182 Although they resorbed a normal 
amount of calcium from their femora, the vitamin D-deficient rats had widened osteoid seams, 
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and increased osteoblast surface, osteoclast number, and resorptive surface. 181 Overall, these 
results indicate that calcitriol, the VDR or vitamin D is not required for bone resorption during 
lactation. 
 
The importance of calcitriol during lactation is further challenged by studies showing that 
intestinal calcium absorption is unaltered by vitamin D deficiency. In one study, vitamin D 
deficient rats on a 0.47 % calcium diet showed a doubling of intestinal calcium absorption 
despite having lower serum calcium and phosphorus, having no difference compared to WT. 180 
Although it is clear that calcitriol is able to stimulate intestinal absorption of calcium, it is 
possible that other hormones are able to compensate in its absence, just as in pregnancy. 
 
1.4 Adaptations during post-weaning recovery and the role of calcitriol 
The time period following lactation is remarkable because it is the only time during adult life 
where the skeleton undergoes complete reversal following bone loss. Bone turnover continues to 
be increased during this time, but is uncoupled to favor bone formation. Specifically, bone 
formation is increasing out of proportion to any change in bone resorption. There are drastic 
changes to the bone microenvironment, due to a reduction in osteoclast number and activity 
prompted by apoptosis of osteoclasts, a substantial decrease in RANKL and RANK expression, 
and a marked increase in osteoblast precursors, osteoblast number, and osteoid surface. 56 
Osteolytic osteolysis also ceases, with osteocytes now expressing genes of the mesenchymal 
lineage and functioning to restore the mineralized matrix. 56 Calciotropic hormones are also 
altered, with decreases measured in PTH and calcitriol and an increase in calcitonin. As a result 
of this combined activity, the human skeleton regains lost mineralization in 3 to 12 months post-
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weaning. 142,170,172,173,176,178,183-185 Several studies have found that not only is the reduction in bone 
loss reversed after lactation has ceased, but there may actually be a protective effect on peak 
bone mass, bone mineral content, and fracture risk. 186-199 In rodents, the recovery of skeletal 
mineral occurs within 2 to 4 wks.140,147-150,152 
 
There is extensive evidence supporting this post-weaning recovery in both humans and rodents. 
Human data are largely based on DXA, and show a complete reversal of the lactational losses in 
bone density, with sooner recovery for shorter intervals of breastfeeding. 56 Femoral structural 
analysis of data from DXA scans shows that decreases in cross-sectional area, cortical thickness, 
and bending strength during lactation were all reversed by 6 months post-weaning. 200 In mice, 
serial studies using DXA, and cross-sectional studies using skeletal ash weight indicate a 
complete recovery of skeletal mineral content. 56 Histomorphometric analysis demonstrates 
recovery of bone volumes, trabecular thickness, and mineral content within two to four wks post-
weaning in the mouse and after four to eight wks in the rat. 56 MicroCT has also been used to 
assess this recovery, revealing full vertebral normalization of bone volumes, trabecular number 
and thickness, mineralization, stiffness, and reversion from a rod-like back to a plate-like 
structure. 150,201 However, persistent alterations have been found in the microarchitecture of tibiae 
and femora using microCT as compared to virgin mice or pre-pregnancy values. 156,201 Despite 
failure of these sites to fully recover the trabecular microarchitecture, biomechanical testing 
shows that strength and stiffness still return to normal. 149  
 
The factors underlying this recovery are largely unknown. Studies investigating intestinal 
calcium absorption have observed relative increases that could facilitate restoration of skeletal 
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mineralization, however the levels are still much lower than those achieved during pregnancy, 
and calcitriol is downregulated. 202 Severely vitamin D-deficient rats improve bone mass and 
architecture after lactation, and VDR null mice also increase BMC to 50 % higher than baseline. 
147,156 PTH also rises to normal following lactation, suggesting it could be involved with 
restoration of mineral to the skeleton, however Pth-null mice fully restore their skeleton above 
baseline BMC post-weaning. 140 Ctcgrp null mice show the most remarkable change during 
lactation with losses of 55 % from lumbar spine BMC, but fully regain it within 18 days post-
weaning. 148,203 Mice with osteoblast-specific ablation of Pthrp also lactate normally and fully 
recover BMC after weaning. Together these studies suggest that vitamin D, VDR, PTH, 
calcitonin, and osteoblast-derived PTHrP are not required to achieve bone formation and post-
weaning recovery in the maternal skeleton.  
 
One study found that a diet of sufficient calcium is required for normal skeletal recovery, as this 
was prevented in rats with a diet low in calcium but normalized three wks later once placed a 
normal diet. 204 Another possible factor could be increased weight bearing post-weaning. Rats 
forced to stand upright to reach their food during lactation and 6 wks following demonstrated 
greater increments in femoral and tibial bone mass. 56 Upregulation of estradiol to normal levels 
may also contribute to skeletal recovery, as demonstrated in humans by an earlier resumption of 
menses in coordination with an earlier increase in BMC following lactation. 142 However, 
osteoblast function is not strongly reliant on estradiol, suggesting that it is not responsible for the 
rapid recovery of bone post-weaning. Collectively, these factors may help contribute to greater 
BMD achievements after weaning, but cannot account for the full recovery in mineralization. 
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Understanding what regulates this phenomenon may enable discovery of new treatments for 
bone loss. The bone recovery seen post-weaning is so unusual because of its rapidity and relative 
completeness, in contrast to other causes of bone loss that are followed by slow and partial, if 
any, recovery. For example, astronauts in space experience bone loss, however have only slow 
and partial recovery upon return to earth. After prolonged stays in space, BMD losses of 2.5-10.6 
% in the lumbar vertebrae and 3-10 % in the femur have been documented. 205 Although follow-
up studies from return to earth are limited, one study measured losses of 4.5 % trabecular bone 
after 6 months exposure to microgravity, and still a 2.55 % decrease present after 6 months 
recovery time. 206 Similarly, bed rest also induces significant bone loss. With 90 days of bed rest, 
bone loss of 6 % in the distal tibia has been reported, along with reduction in cortical bone 
thickness and density of greater than 2 %.207 Moreover, the use of GnRH analog treatment for six 
months causes estrogen-deficiency bone loss in women of reproductive age that is not recovered 
more than a year after estrogen status has returned to normal. 56 Numerous other conditions 
induce active resorption of bone, such as osteoporosis or Paget’s disease. Although an extensive 
amount of research has been conducted, the available treatments are still less effective than the 
full recovery seen following weaning.  
 
1.5 Possible non-VDR mediated actions of calcitriol 
The classical role of calcitriol in regulating mineral metabolism has been explained in depth. It 
binds stereospecifically to the vitamin D receptor to activate or repress target genes. In the adult, 
calcitriol has an antirachitic effect on bone, increases the efficiency of intestinal calcium 
absorption with increased demand for calcium as a result of growth, and enhances calcium 
transport in the kidney. As previously described, the regulatory systems invoked during 
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pregnancy, lactation, and post-weaning recovery may only partially depend on vitamin D or 
VDR, as they persist despite knockout animal models. Still, the question remains whether 
calcitriol is required.  
 
Although the only known receptor for calcitriol is the vitamin D receptor, non-VDR mediated 
effects of calcitriol have been extensively suggested throughout the literature. One example of 
these putative non-genomic actions of calcitriol is in post-weaning skeletal recovery of Vdr null 
mice. Although they undergo substantial increases in BMC and intestinal calcium absorption 
during pregnancy, resorb the skeleton normally during lactation and recover fully post-weaning, 
the knockout mice were found to have high circulating levels of calcitriol in comparison to their 
WT sisters. 128,147 Therefore, it remains conceivable that calcitriol is able to act through 
alternative signalling mechanisms to mediate the normal skeletal and intestinal adaptations of 
reproduction. 
 
Further research is provided by Lai and colleagues, who comment on the range of biological 
effects calcitriol has on the body. 208 They suggest that such varied effects as transcaltachia (the 
rapid stimulation of intestinal calcium absorption), phosphoinositide turnover, and the induction 
of protein kinase C, phospholipase A2, guanylate cyclase and alkaline phosphatase cannot be 
explained by VDR-mediated gene expression. A possible specific calcitriol membrane coupled 
receptor explaining transcaltachia was isolated from the intestinal membranes of chicks, and 
named the calcitriol-membrane-associated rapid response to sterioid. 209 This receptor was found 
to mediate rapid responses to calcitriol, including phospholipase A2 activation, membrane 
fluidity, and phospholipase C activation, which leads to the activation of protein kinase C and 
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intracellular calcium release (Figure 6). 210 These responses occurred either within seconds, or 10 
to 60 minutes. Comparatively, hours are required for the genomic actions of calcitriol to occur. 
211 However, the existence of this specific receptor is still up for debate, as evidence suggests that 
calcitriol can bind to an alternative ligand pocket on the VDR to mediate these rapid non-
genomic responses. 212  
 
Another hypothetical pathway for the alternative signalling mechanisms is through VDR 
participation in signal transduction, rather than the classical route of transcriptional regulation 
(Figure 6). Buitrago and colleagues indicated this non-transcriptional participation by showing 
that calcitriol stimulated rapid survival/proliferation responses in skeletal muscle cells. 212 
Specifically, calcitriol activated MAPKs and phosphorylated Src. This effect was abolished 
when VDR expression was reduced, suggesting its interaction in the pathway. 212  
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Figure 6: Hypothetical alternative signalling mechanisms of calcitriol in skeletal muscle 
cells. 212 Calcitriol may act through an unknown membrane receptor to mediate rapid responses 
via PLC/PKC, which could contribute to intracellular calcium release. Calcitriol may also act 
through the VDR in an alternative signalling pathway via phosphorylation of Src and MAPK 
activation to induce cellular survival, proliferation, and differentiation. Copyright, Elsevier 
(Appendix D). 	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1.6 Rationale, hypothesis, and objectives 
Calcitriol has numerous essential roles to regulate bone and mineral metabolism in the adult. 
However, vitamin D and VDR are not required for the intestinal and skeletal adaptations to 
pregnancy, lactation, and post-weaning. It is unknown whether calcitriol can act independently 
of the vitamin D receptor to regulate these changes during reproductive cycles.  
 
Our hypothesis is that calcitriol is required for upregulation of intestinal calcium absorption 
during pregnancy and post-weaning, and to enable normal recovery of bone mass post-weaning, 
such that the high levels seen in the Vdr null mice are acting through alternative signalling 
mechanisms to have these effects. If correct, then loss of calcitriol would impair intestinal 
calcium absorption and bone metabolism during the reproductive cycle and would lead to effects 
that loss of VDR does not. This would also promote further study to identify the other 
mechanistic pathways through which calcitriol acts. If the data lead to rejection of my 
hypothesis, this would confirm that calcitriol is not required for regulating intestinal and bone 
metabolism during reproduction, and would underscore the need to identify factors that do 
regulate intestinal calcium absorption and bone metabolism during pregnancy, lactation, and 
post-weaning.  
 
We tested our hypothesis by examining a mouse model with the Cyp27b1 gene ablated. These 
knockout mice lack the enzyme that synthesizes calcitriol. Studies were performed comparing 
sister Cyp27b1 null and WT pairs raised on a rescue diet from the time of weaning. Rigorously 
comparing WT and Cyp27b1 null mice that were first degree relatives of each other and mated to 
the same males allowed for stronger comparisons where differences could be attributable to 
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genotype rather than genetic drift from breeding. The research aimed to investigate (1) bone 
mineral content by DXA, (2) blood and urine biochemistry, (3) skeletal microarchitecture of 
femurs and lumbar vertebrae by µCT, (4) cortical bone strength by 3-point bend test, and (5) 
intestinal calcium absorption at pre-pregnancy baseline, end pregnancy, end lactation, days 7, 14, 
21, and 28 of post-weaning recovery, and virgin age-matched controls to the recovery day 28 
samples. Through contrasting the phenotypes and looking for evidence of compensation in the 
absence of calcitriol, it should become apparent whether or not calcitriol contributes importantly 
to the regulation of skeletal and mineral homeostasis during the reproductive cycle. 
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II. MATERIALS AND METHODS 
2.1 Mouse model 
Cyp27b1 null mice were provided by Dr. René St-Arnaud at McGill University in Montreal, 
Quebec. The Cyp27b1 enzyme was inactivated by Cre-mediated excision of the gene in 
embryonic stem cells. Homologous recombination with the targeted-1αOH locus and wild-type 
locus between two loxP sites flanking exon 8 deleted the heme-binding domain. Effectively, this 
created a null allele. 30 Three genotypes result from mating heterozygous males and females 
together: wild type with both normal Cyp27b1 alleles (Cyp27b1+/+), heterozygous (HET or 
Cyp27b1+/=) with one normal Cyp27b1 allele and one Cyp27b1 allele ablated, and null with both 
Cyp27b1 alleles ablated (Cyp27b1-/-).  
 
2.2 Genotyping 
2.2.1 Animal identification 
At 21 days of age, experimental mice were weaned from their mothers and separated into cages 
based on sex, with a maximum of 4 mice per cage. Mice were briefly anesthetized under 
isoflurane, and their right ear was crimped with a tag denoting mouse strain and number.   
 
2.2.2 Tail sample collection 
While still under the anesthetic from ear tagging, a 0.5 cm section of tail was cut with a sterile 
razor blade and placed into a 1.5 ml eppendorf tube labeled with the mouse identification. To 
digest the tail section, 300 µl of cell lysis solution and 1.5 µl of proteinase K was added to each 
tube, and samples were placed in the incubator (Fisher Scientific, Burlington, ON) at 55ºC 
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overnight. Bleeding was stopped by applying a small amount of pressure to the tail. Mice 
recovered from anesthesia in a separate clean cage.  
 
2.2.3 DNA extraction 
The following day, DNA extraction was conducted as per the Qiagen Puregene® Core Kit A 
(Qiagen, Toronto, ON). Digested tail samples were removed from the incubator and 100 µl of 
protein precipitation solution was added to each tube. Samples were mixing using a vortex for 20 
s on high speed, and then centrifuged for 3 mins at 16,000 x g. Following precipitation of the 
proteins, 300 µl of isopropanol was pipetted into a clean 1.5 ml microcentrifuge tube, and the 
supernatant from the previous step was decanted. Tubes were inverted 50 times to precipitate the 
DNA, and then centrifuged for 1 min at 16,000 x g to attain a pellet. After centrifugation, the 
supernatant was discarded and 300 µl of 70 % ethanol was added. To wash the DNA pellet, the 
tubes were inverted several times and centrifuged for 1 min at 16,000 x g. The supernatant was 
again decanted and the tube was drained on a piece of absorbent paper, and excess ethanol was 
removed with a pipette. The ethanol was further allowed to evaporate by leaving the tubes open 
for 5 mins. Following air dry, 100 µl of DNA hydration solution was added, and samples were 
vortexed for 5 s. Lastly, samples were incubated at 65 ºC for a time period of 1 hr to solubilize 
the DNA.  
 
2.2.4 Polymerase chain reaction (PCR) 
PCR was carried out on the DNA collected from mice tails using a three-primer system. The 
forward primer detected both the WT and null allele, while primers 2 and 3 separately detected 
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the Cyp27b1 null allele and Cyp27b1 WT allele, respectively. Specifically, the primer sequences 
were as follows: 
Cyp27-1 (forward): 5’ - AAT TCC CGT GTC CCA GAC AGA GAC ATC C – 3’ 
Cyp27-2 (reverse): 5’- GGT CAT GGG CTT GAT AGG AAG AGC ACC – 3’ 
Cyp27-3 (reverse): 5’- GGG TGG GGA ATG TGA AGA AGA GGA TCT G – 3’ 
As a result of primer 2 annealing to the DNA template downstream to primer 3, the Cyp27b1 null 
mice were identified by a larger transcript than the WT mice. Specifically, the product of two 
primers for the null Cyp27b1 allele was 350 bp, whereas a 250 bp product resulted from two 
primers for the WT Cyp27b1 allele (Figure 7). 
 
The PCR cocktail was made with 10x PCR reaction buffer, deoxyribose nucleotide tri-
phosphates (dNTPs – dATP, dTTP, dCTP, dGTP), primers (Cyp27-1, Cyp27-2, Cyp27-3), 
MgCl2, Taq DNA polymerase, and distilled water (Invitrogen, Burlington, ON). A 19.5 µl 
aliquot of this cocktail was pipetted into each labeled reaction tube with 2 µl of DNA.  Tubes 
were then placed in the PCR machine. 
 
The entire PCR program consisted of 7 steps to amplify the respective DNA sequences, which is 
described as follows: Step 1: 94°C for 5 mins to initialize the reaction, Step 2: 94°C for 30 s to 
denature the DNA, Step 3: 58°C for 30 s to anneal the primers, Step 4: 72°C for 30 s to 
synthesize and elongate a complementary strand, Step 5: return to step 2 and repeat for 35 cycles 
for continued amplification, Step 6: 72°C for 10 mins to elongate any remaining strands and Step 
7: 4°C for storage of the reaction. 
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2.2.5 Gel electrophoresis 
Gel electrophoresis was performed to separate and analyze the DNA fragments from the PCR 
program using a 1.2 % agarose gel. Specifically, the gel was made with 100 ml 10X TAE (0.12 
M EDTA, 0.40 M Tris, 11.5 % Glacial Acetic Acid, pH 8.0), 900 ml deionized water, 1.2 g 
agarose (Invitrogen), and 10 µl SYBR Safe DNA Gel Stain (Invitrogen). The TAE was diluted to 
a 1X buffer solution, and the agarose was dissolved in 100 ml by microwaving at two separate 
intervals of 1 min. The gel stain was added to the solution and swirled. The solution was then 
poured into the casting tray and left for 30 mins to polymerize. During this time, 4 µl of 6x 
loading dye (10 mM Tris, 0.03 % bromophenol blue, 0.03 % xylene cyanol FF, 60 % glycerol, 
60 mM of 0.5 M EDTA, 1.5 M dH2O) was added to each of the 21.5 µl PCR products.  
 
Following solidification of the gel, 800 ml of running buffer (720 ml deionized water and 80 ml 
10X TAE) was added to the gel electrophoresis chamber and the gel inserts were carefully 
removed. 15 µl of PCR product and the loading dye mix was injected into each well of the gel. 
After loading, the samples were run at 200 V for 20 mins.  
 
The bands were visualized under UV light using the Kodak Gel Doc System. The results were 
imaged using Bio-Rad Image Lab version 5.1. The presence of a single band at 250 bp indicated 
the mouse was WT, a single band at 350 bp indicated the mouse had two copies of the mutated 
allele and was therefore Cyp27b1 null, and the presence of both bands indicated the mouse was 
heterozygous for the ablated allele (Cyp27b1+/-) (Figure 8).  
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Figure 7: Schematic of the alignment of primers used to distinguish the retained and 
deleted portions of the Cyp27b1 gene. HET, WT, and Cyp27b1 null mice were identified by 
PCR using a 3-primer system. Primer 1 detected both the WT and null allele, primer 3 detected 
the WT allele, and primer 2 detected the null allele. 
 
 
 
 
               HET  HET   WT   HET NULL WT  
	  
 
 
Figure 8: Genotyping by PCR and gel electrophoresis. Sample PCR products run on a 1.2 
% agarose gel. The presence of both 250 bp and 350 bp bands represents a heterozygous mouse, 
the presence of a single 250 bp band indicates a WT mouse, and the presence of a single 350 bp 
band indicates a null mouse. 
 
350bp 
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2.3 Animals 
2.3.1 Rescue diet and water 
Both WT and Cyp27b1 null mice were placed on a rescue diet (TekLad TD.94112; Harlan 
Teklad, Madison, WI) at weaning to allow for normal conception rates and a normal phenotype 
in the nulls. 33,38,130 This consisted of 2 % calcium, 1.25 % phosphorus, and 20 % lactose. Tap 
water was triple filtered using a 0.2, 1, and 5 µm component system and was available ad 
libitum. The filtration system removes dirt, sediment, sand, rust, and scale particles. Dissolved 
calcium was likely not filtered out using this method.  
 
2.3.2 Scheduled mating and litter sizes 
Light and dark cycle was used for housing mice, with light from 08:00 to 20:00. Mice utilized 
for generating the colony were not scanned for BMC, and therefore could be mated as early as 8 
wks of age. HET by HET matings were established to generate a colony of all genotypes 
according to Mendelian genetics. Virgin first-degree relative pairs of WT and Cpy27b1 null 
females were selected for study at 10 wks of age, at which time bone mass has reached a 
relatively stable plateau. Baseline measurements on experimental mice were conducted at this 
time. Consequently, females were placed with heterozygous breeding males at approximately 
16:00 hrs on Thursdays. After mating overnight, mice were manually checked for presence of a 
vaginal mucus plug at approximately 9:00 hrs the morning after mating. The presence of a plug 
indicated that the female had mated and may have conceived; if so this was gestational day 0.5. 
However, a plug was not always evident because it was too small or had already fallen out. Mice 
were placed back in original group housing cages and mated again the following Thursday until 
pregnancy was visually confirmed. After visual confirmation mice were placed into single 
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housing cages. Normal gestation for these mice was 18.5 days. Lactation lasted 21 days, and was 
ensured by weaning the pups from the mother on this day. Litter sizes were counted at the time 
of weaning. Mice used as virgin controls were left unmated and harvested at the same time as 
day 28 of recovery to coincide with mated mice.  
 
2.4 Reproductive cycles 
Full reproductive cycles lasted a minimum of 82 days (Figure 9). Pre-pregnancy was defined as 
the 14 days prior to being placed with a breeder male and after the female had reached 10 wks of 
age. Pregnancy spanned 18.5 days and lactation occurred over 21 days. Weaning was defined as 
the day in which the suckling pups were manually removed from the mother, and post-weaning 
spanned 28 days, even if BMC had recovered prior to that point. Recovery was analyzed at 4 
stages for experimental purposes: 7 days, 14 days, 21 days, and 28 days.   
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Figure 9: Schematic time line of data collection throughout the reproductive cycle in mice. 
Samples of serum, urine, and bone were collected in addition to DXA scans at various time 
points throughout the reproductive cycle. 
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2.5 Data collection and storage 
2.5.1 Litter sizes 
Litter numbers were counted at the time of weaning (21 days post-partum) for both WT and 
Cyp27b1 null mice. This number was used rather than the number of pups initially birthed by the 
mother, since mice often cull their litters over the first several days. If the WT or null mothers 
however were nursing different numbers of pups, I was prepared to cull the litters after birth. 
 
2.5.2 Urine 
Prior to every BMC scan, each mouse was placed into a separate clean and empty cage in order 
to void. Urine was collected with a pipette into 0.6 ml microcentrifuge tubes and stored at -20 ºC 
until time of assay. Maternal urine samples were collected at baseline, day 18.5 of gestation, day 
21 of lactation, and weekly for the 4 wks of recovery. 
 
2.5.3 Blood 
Blood samples of serum were taken by bleeding the tail vein for longitudinal sampling and by 
cardiac puncture for terminal samples. Tail vein blood was taken after each BMC scan while the 
mouse was still under anesthetic (single intraperitoneal injection of a 20 uL mixture of 50 mg/ml 
ketamine and 20 mg/ml xylazine). A small section of tail was cut with a razor blade, and the 
blood was massaged out and collected into a 0.6 ml microcentrifuge tube. A small amount of 
pressure was applied to the tail to stop the bleeding. Sample was then centrifuged for 
approximately 7 mins to separate the serum from packed red cell volume. The serum was 
pipetted into a newly labeled 0.6 ml microcentrifuge tube and stored in the -20 ºC freezer. 
Alternately, cardiac puncture was performed prior to euthanasia in order to obtain larger blood 
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volumes. For this procedure, mice were temporarily anesthetized under isoflurane, and then held 
firmly in one hand to prevent limb or head movement. Sterile 1 cc syringes were attached to 20 
gauge needles and skin was pierced beneath the mouse ribcage at a slight angle to penetrate the 
heart. Blood from the heart was then drawn into the syringe and emptied into 1.5 ml 
microcentrifuge tubes. The mother was then killed by cervical dislocation. Samples were 
subsequently spun on a microcentrifuge for approximately 7 mins at 16000 x g to separate out 
serum from clotted blood. Serum was then pipetted into a newly labeled 1.5 mL microcentrifuge 
tube and stored in the -20ºC freezer until time of assay. 
 
Plasma was collected from mice used in the intestinal calcium absorption experiments. Blood 
samples were taken by cardiac puncture as described above. Following cervical dislocation, 
blood from the syringe was emptied into heparinized tubes. Samples were kept in a -20ºC freezer 
designated for radioactive samples until analysis.  
 
2.5.4 Bone  
Femur, tibia, fibula, and lumbar spine were harvested at specific time points of the mouse 
reproductive cycle (baseline, lactation, recovery 1, and recovery 4) in addition to virgin age-
matched controls to the recovery 4 mice (Figure 9). Mice were initially anesthetized with 
isoflurane and then killed by cervical dislocation. Hair and flesh were removed using forceps and 
scissors. A coronal incision was cut across the ventral torso to expose the vertebral column. The 
lumbar vertebrae were isolated using a complete transverse incision at the pelvic line and 
cervical line, including extra thoracic vertebrae to avoid errors. The heads of the femurs were 
then carefully separated from the ileum and pubis through the application of slight pressure to 
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the joint with scissors. Tibia and fibula were isolated from the femur using scissors. Storage 
methods differed depending on the intended future analysis, which will be explained in each 
corresponding section. 
 
2.6 Bone mineral content 
BMC was measured using the PIXImus 2 DXA. To ensure standardization of measurements, a 
quality control scan was performed with a “phantom” mouse (BMD=0.0630 g/cm, % fat =11.9 
%) to calibrate the machine. As stated by the manufacturer, the precision of the DXA machine is 
3.31 % for BMC (GE Lunar PIXImus, Madison, WI). Excess calcium from the diet found in the 
gut could artificially increase the apparent whole body and lumbar spine BMC reading as DXA 
measures calcium regardless of whether it is found in bone or outside the skeleton. To minimize 
this inaccuracy, all mice were fasted 18 hrs prior to DXA scans. 
 
Mice were prepared for the scans with anesthesia to minimize movement of the head and limbs. 
Initial anesthesia was induced using isoflurane poured onto paper towel in a small glass chamber. 
This was followed by an intraperitoneal (IP) injection of a 20 uL mixture of Ketamine (50 
mg/ml) and xylazine (20 mg/ml). Once anesthetized, mice were placed on holding trays with a 
specific orientation to allow for precise BMC measurement and reproducibility. Spines were 
manually straightened, arms were extended perpendicular to body, paws were placed flat, and the 
tail was curved around the left side of the torso. For all scans, the head was excluded due to a 
large amount of variability within the region, in addition to keeping the ear tag from confounding 
the scan. Thus, only the body and limbs were included in the BMC measurements.  
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Scans were analyzed for whole body (minus head and neck), lumbar spine, and hind limb BMC 
measurements in grams (Figure 10). Lunar PIXImus software allowed for the region of interest 
(ROI) to be adjusted to isolate the lumbar spine, hind limb, and to exclude an area of head or ear 
tag scanned.  
 
Bone mineral content was measured using the previously mentioned scheme at baseline, late 
pregnancy, late lactation, and 4 wks of recovery (Figure 9). A minimum of 2 baseline scans were 
performed on each mouse one week apart to ascertain an average pre-pregnancy value and 
confirm that BMC had reached a steady plateau. Further baseline scans were performed if there 
was a BMC difference >5% or if the mouse did not become pregnant after three weeks. BMC 
values were reported by absolute value, and as relative changes to the initial averaged baseline 
value prior to mating. To calculate the relative changes for recovery, the fourth recovery BMC 
measurement was used.  
 
BMC measurements were collected using two different methodologies. In the first, mice were 
fasted overnight and left in their original cage to be scanned the following day. In the second 
revised analysis, mice were changed to a new cage in attempts to limit coprophagia, and 
similarly fasted overnight.  
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A)  B)	    
                                     C) 	  
Figure 10: Representative scans of whole body, lumbar spine, and hind limb BMC 
measurements. DXA scans were taken at the main reproductive time points. In each scan, the 
green box identifies the region of interest. A) Representative scan of whole body BMC. The red 
circle is used to exclude the head and neck, due to a large amount of variability in this region. B) 
Representative scan of the lumbar spine, as identified by the 6 vertebrae selected. C) 
Representative scan of the hind limb, including the femur, tibia, and fibula.  
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2.7 Mineral assessment 
2.7.1 Serum and urine total calcium measurement 
The test principle of the total calcium assay is that calcium reacts with Arsenazo III in an acid 
solution. 213 The calcium-Arsenazo complex develops a blue-purple colour with a maximal 
absorbance at 650 nm. Results read at this wavelength are directly proportional to the total 
concentration of calcium in the sample. Both serum and urine were measured at the main time 
points (Figure 9) using samples from the first DXA set. Reportable range of the kit (Sekisui 
Diagnostics, Charlottetown, PEI) was 0.01 mmol/L to 3.75 mmol/L. For urine, the assay was 
first performed using a saline dilution of 1:10. Values were read lower than the reportable range, 
so the kit was repeated using undiluted urine. Serum samples were also measured undiluted. All 
samples were measured in duplicate if possible and followed kit instructions. A 
spectrophotometer (Ultraspec 2000; Pharmacia Biotech, Piscataway, NJ) was used to read the 
absorbance at 650 nm. Final urine results were corrected for by the concentration of creatinine 
(mmol Ca/mmol Creatinine). Deionized water was used as a blank.  
 
2.7.2 Serum and urine inorganic phosphate measurement 
The test principle of the phosphorus assay is that inorganic phosphorus reacts with ammonium 
molybdate in the presence of sulfuric acid to produce an unreduced phosphomolybdate complex. 
214 The concentration of inorganic phosphorus in each sample is directly proportional to the 
increase in absorbance at 340 nm. Serum and urine were measured at the main time points 
(Figure 9) using samples from the first DXA set. Reportable range of the kit (Sekisui 
Diagnostics, Charlottetown, PEI) was 0.03 mmol/L to 6.46 mmol/L. For urine, the assay was 
initially performed using a saline dilution of 1:10. Samples measured outside of the reportable 
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range were then repeated either with a dilution factor of 1 or 100. Serum samples were measured 
undiluted. All samples were measured in duplicate if possible and followed kit instructions. A 
spectrophotometer (Ultraspec 2000; Pharmacia Biotech) was used to read the absorbance at 340 
nm. Final urine results were corrected for by the concentration of creatinine (mmol P/mmol 
Creatinine). Deionized water was used as a blank.  
 
2.7.3 Urine creatinine measurement 
The test principle of the creatinine-S assay is that creatinine reacts with picrate in an alkaline 
environment to produce a creatinine-picrate Janovsky complex. 215 The concentration of 
creatinine in each sample is directly proportional to the rate of increase in absorbance at 510 nm. 
This assay was performed as a calculation basis for normalizing the values of all other urinary 
metabolites. Urine samples at the main time points of the reproductive cycle were tested (Figure 
9) using samples from the first DXA set. Reportable range of the kit (Sekisui Diagnostics, 
Charlottetown, PEI) was 4 µmol/L to 1945 to µmol/L. All samples were measured in duplicate 
using a saline dilution of 1:10, and followed the procedure in the kit. A spectrophotometer 
(Ultraspec 2000; Pharmacia Biotech) was used to read the absorbance at 510 nm. Deionized 
water was used as a blank.  
 
2.8 Hormone physiology 
2.8.1 Serum parathyroid hormone (PTH) 
Mouse serum PTH was measured using a Mouse Intact PTH Enzyme-linked ImmunoSorbent 
Assay (ELISA) Kit (Immunotopics Inc, San Clement, CA.). The detection limit of the assay was 
4 pg/ml. The test principle applies two-site ELISA methodology to determine serum PTH 
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concentration. 216 Intact PTH contains 84 amino acids. The C-terminal portion is recognized by 
an anti-mouse PTH antibody anchored to the well surface and is biotinylated for capture. The N-
terminal portion is recognized by a horseradish peroxidase (HRP)-labeled anti-mouse antibody, 
and forms a sandwich complex with the capture antibody. The enzymatic activity of the antibody 
complex bound to the well is directly proportional to the amount of PTH in the sample. Serum 
samples from the first DXA set were measured at baseline, late pregnancy, late lactation and 
recovery 1. Experiments followed the kit procedure in duplicate. Results were first read at 450 
nm in a microplate spectrophotometer (Epoch; Biotek, Winooski, VT) and analyzed using Gen5 
software (Version 2.04.11, BioTek Instruments Inc). A large number of the PTH values for the 
Cyp27b1 null mice were above the detection limit of the reader. As per the kit protocol, the plate 
was read again at 620 nm to extend the analytical range to the highest standard, and these values 
were used for analysis. 
 
2.8.2 Serum calcitriol 
Mouse serum calcitriol was measured using a 1,25-Dihydroxy Vitamin D Enzyme Immunoassay 
(EIA) kit intended for human samples but validated in mice (Immunodiagnostic Systems, Inc, 
Gaithersburg, MD). The manufacturer’s limit of the assay for human serum was 6 pmol/L. The 
assay was performed over two days, using immunoextraction to purify calcitriol in serum then 
quantification by EIA. The methodology was based on competitive binding of either free 
calcitriol or calcitriol linked to biotin for a limited amount of highly specific sheep anti-calcitriol 
binding sites. 217 The amount of complexed biotin bound to the anti-sheep antibody was inversely 
proportional to the concentration of calcitriol. The assay was carried out in single, using 120 µl 
of undiluted serum measured at baseline, late pregnancy, and late lactation. Kit instructions 
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followed the alternative sample preparation and remaining immunoextraction and assay 
procedure. Results were read at 450 nm in a microplate spectrophotometer (Epoch; BioTek) and 
analyzed using Gen5 software. 
 
2.8.3 Serum fibroblast growth factor 23 (FGF23) 
Mouse serum FGF23 was measured using an FGF23 ELISA Kit (Kainos Laboratories, Tokyo, 
Japan). The detection limit of the assay was 3 pg/ml. The test principle is a two-step ELISA. 218 
Generally, FGF23 is captured by an immobilized FGF23 antibody at the plate surface of the 
well; the HRP-labeled FGF23 antibody then forms a sandwich complex with the first antibody. 
The enzymatic activity of the antibody complex bound to the well is directly proportional to the 
amount of FGF23 in the sample. Serum samples from both DXA sets were measured at baseline, 
late pregnancy, late lactation and recovery 1. Experiments followed the kit procedure in 
duplicate. Results were read at 450 nm in a microplate spectrophotometer (Epoch; Biotek) and 
analyzed using Gen5 software.  
 
2.9 Markers of bone turnover 
2.9.1 Serum procollagen type 1 N-terminal peptide (P1NP) 
Procollagen type 1 N-terminal propeptide (P1NP), a bone formation marker, was measured in the 
serum of WT and Cyp27b1-/- mice at baseline, late pregnancy, late lactation, and recovery 1 
using samples from both DXA sets. An EIA kit for P1NP (Inter Medico, Markham, ON.) was 
used for analysis. The detection limit has not been reported. The assay is based on the principle 
that type 1 collagen is synthesized during bone formation, to comprise the majority of the 
organic component in bone matrix. 219 During the synthesis of collagen, the amino- and 
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carboxyterminal ends of the procollagen molecule release propeptides that are secreted into 
blood circulation. Enzyme immunoassay is therefore able to detect these propeptides. In this 
manner, the serum concentration of P1NP reflects the rate of bone formation. Specifically, the kit 
is a competitive EIA that uses a polyclonal rabbit anti-P1NP antibody to coat the inner surface of 
the microtitre wells. Experiments followed the procedure in the kit in duplicate. Results were 
read at 450 nm in a microplate spectrophotometer (Epoch; Biotek) and analyzed using Gen5 
software, with colour intensity being inversely proportional to the concentration of P1NP.   
 
2.9.2 Urine deoxypyrodinoline 
Deoxypyrodinoline (DPD), a bone resorption marker, was measured in the urine of WT and 
Cyp27b1-/- mice at baseline, late pregnancy, late lactation, and recovery 1 using samples from the 
first DXA set. An EIA kit for DPD (Quidel, San Diego, CA.) was used for analysis. The 
detection limit of the assay was 1.1 nmol/L. The assay is based on the principle that type 1 
collagen of bone is crosslinked by pyridinoline (PYD) and deoxypyridinoline, which provide 
rigidity and strength. 220 DPD is formed from an oxidation reaction of the amino acid lysine, and 
is released into circulation when bone is resorbed. As DPD is unaffected by diet and excreted 
unmetabolized in urine, it is a suitable candidate for the assessment of bone resorption. In this 
manner, elevated levels of urinary DPD indicate elevated bone resorption levels. The kit is a 
competitive EIA that uses a monoclonal anti-DPD antibody to coat the inner surface of the 
microtitre wells. Experiments followed the kit procedure in duplicate. Results were read at 405 
nm in a microplate spectrophotometer (Epoch; Biotek) and analyzed using Gen5 software, with 
colour intensity being inversely proportional to the concentration of DPD. Final results were 
corrected for by the concentration of creatinine (nmol DPD/mmol Creatinine).  
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2.10 Micro-computed tomography (µCT) 
WT and Cyp27b1 null mice were killed by cervical dislocation at baseline, late lactation, 
recovery 1, recovery 4, and virgin mice age-matched to the recovery 4 mice. Initially for mice at 
recovery 4, the top three lumbar vertebrae were harvested together and surrounding tissue was 
removed using a sterile blade and scissors. Tibias were similarly harvested with removal of 
surrounding tissue, and the fibula was kept on to allow for easier orientation analysis. Both 
lumbar vertebrae and tibias were stored together in scintillation vials filled with formalin until 
analysis.  
 
Femurs were also collected for µCT, and these were harvested with surrounding muscle tissue 
attached, to avoid damaging the sample. Femurs were stored with the hind limbs in 70 % 
ethanol, due to the preference of the St. Vincent’s Institute of Medical Research. Samples were 
analyzed by Brett Tonkin and guidance was provided by Dr. Natalie Sims at the University of 
Melbourne. It was performed using a high resolution µCT scanner (Skyscan 1076, Kontich, 
Belgium). Images were acquired using 9 mm voxel resolution, 0.5 mm aluminum filter, 50 kV 
voltage, and 100 mA current. The exposure time was set at 2600 ms, the rotation set at 0.5 
degrees, and frame averaging = 1. Reconstruction and analysis of the images was performed 
using Skyscan software programs NRecon (version 1.6.3.3), DataViewer (version 1.4.4), and CT 
Analyzer (version 1.12.0.0). Femoral trabecular analysis region of interest (ROI) was performed 
15 % above the distal end of the femur toward the femora mid-shaft, with a 12.6 % ROI and 
threshold values set as 40-255. Cortical analyses were performed 35 % above the distal end of 
the femur toward the femora mid-shaft, with a 12.6 % ROI and threshold values set as 85-255. 
Reconstruction limits were set at low: 0.000 and high: 0.138.  
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2.11 3-Point bend test 
Tibias from both WT and Cyp27b1 null mice were harvested at baseline, late lactation, recovery 
1, and recovery 4. Adjacent tissue was removed in addition to the fibula that was broken off. 
Specimens were kept frozen at -20ºC until the night before testing. To thaw, tibias were placed at 
room temperature in 1X PBS. Cortical bone strength was tested using a 3-point bend fixture 
attached to an Instron Series 3340 electromechanical single column test instrument (Instron, 
Norwood, MA) together with the Instron Series IX/s software package. The platform was labeled 
to place each tibia evenly on the same location, and each tibial end was fixed. The crosshead was 
lowered so that the 10 N load cell was located approximately 2-3 cm above the midshaft of the 
tibia. The machine was balanced prior to each analysis, after which point the start button was 
activated and the crosshead descended at 10 mm/min. The descent of the crosshead continued 
until the tibia bone was broken. The software displayed numerous biomechanical parameters, of 
which maximum load (gf), displacement (µm), maximum strain (gf/mm2), maximum strain (%), 
and slope (gf/mm) were manually recorded.   
 
2.12 Intestinal calcium absorption 
Intestinal 45Ca absorption assay was performed according to previously described methods. 221 
The radioactivity accumulated in the blood after oral gavage was used as an indirect measure of 
intestinal calcium absorption. Cyp27b1 null and WT mice were studied at baseline, day 17.5 of 
pregnancy, and recovery 1. Day 17.5 of pregnancy was selected instead of 18.5 days so as to 
avoid premature birth while allowing sufficient time for intestinal absorption to reach its peak 
value. Four heterozygous females were used and averaged as quenching controls. All mice were 
fasted 18 hrs prior to analysis. Experimental mice were given 0.2 ml of a solution containing 8 
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ml of buffer (10 mM Tris-acetate pH 7.5 and 0.5 mM CaCl2) and 1 µl 45Ca via gastric gavage. In 
this manner each mouse received 0.5 µCi 45Ca. Mice were held firmly at the scruff of the neck 
and feeding needle attached to filled syringe was slid along the roof of the oral cavity. The 
feeding needle was inserted into the esophagus, where the contents of the syringe were released. 
Feeding needle was then removed and mouse was placed in a cage specific for radioactive 
studies. After a 45 min waiting period following administration of the 45Ca, experimental mice 
were temporarily anesthetized with isoflurane and blood was collected by cardiac puncture. 
Blood was injected into a heparinized tube and mice were then immediately killed via cervical 
dislocation. All blood samples were stored at -20 ºC until analysis. To determine the 
radioactivity accumulated, an aliquot of 100 µl of whole blood from each wild type and Cyp27b1 
null mouse were counted with 10 ml scintillation fluid in a multi-purpose scintillation counter 
(Beckman Coulter, U.S.A). 
 
2.13 Statistical analysis 
StatPlus 5.8.3.8 for Macintosh (AnalystSoft Inc, Vancouver, BCF) was used for data analysis. 
Differences among means were calculated by one-way ANOVA (analysis of variance) with post-
hoc tests (unstacked), and the Tukey-Kramer test was used to determine which differences were 
statistically significant. All data are presented with ± standard error (SE). On the graphs, 
significant differences are marked, and the number of samples studied is indicated in parentheses 
on the x-axis. 
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2.14. Animal care approval 
All studies involving live mice were performed with the prior approval of the Institutional 
Animal Care Committee of Memorial University. 
	   79	  
III. RESULTS 
3.1 Litter sizes 
To measure changes in BMC throughout the mouse reproductive cycle, it is extremely important 
to have the WT and null mothers well-matched for litter size, especially during lactation. The 
number of pups nursed during this time period will determine the amount of calcium required, 
and therefore the amount of bone resorbed from the maternal skeleton and the amount of calcium 
absorbed from the intestines. The breeding pairs involved in this study proved to be well-
matched (Figure 11) with litter sizes of 5.2 ± 0.7 and 5.1 ± 0.7 for WT and Cyp27b1 null, 
respectively (p=NS). The litters were not culled as both types of dams nursed the same number 
of pups on average.  
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Figure 11: Average number of pups nursed by experimental mothers. At weaning, the litter 
sizes were equal between WT and Null mothers. Values are means ± SE and sample sizes are 
indicated in parentheses. 
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3.2 Bone mineral content 
3.2.1 First analysis of BMC excursion 
Despite prior studies showing that the rescue diet allowed the Cyp27b1 null mice to develop 
normally without rickets, at baseline Cyp27b1 nulls had 30 % lower whole body BMC than WT 
(0.417 ± 0.028 g and 0.563 ± 0.017 g, respectively) (Figure 12).  33,38,130 Absolute changes of 
whole body BMC of both genotypes throughout the reproductive period are shown in Figure 13. 
The whole body measurement is largely an indicator of cortical bone.  WT mice do not show any 
statistically significant changes across the reproductive cycle. During pregnancy, Cyp27b1 null 
mice significantly increase their BMC, and then experience a significant decrease during late 
lactation. Between genotypes, the BMC increase in the nulls during pregnancy results in a 
similar value to WT (0.628 ± 0.023 g in WT and 0.556 ± 0.025 g in Cyp27b1 null). The Cyp27b1 
null females lose more BMC than WT during lactation, such that the null BMC value is 
significantly lower than WT (0.567 ± 0.027 g in WT and 0.412 ± 0.031 g in Cyp27b1-/-).  The 
relative changes in whole body BMC are shown in Figure 14. It is shown that both genotypes 
had BMC increases from baseline to late pregnancy, with an 11.9 ± 1.9 % increase in WT and 
43.6 ± 13.5 % increase in null. Although the null mice have resorbed more bone during lactation, 
both genotypes are at a similar degree below baseline at late lactation. Subsequently, WT and 
null recover to a value above pre-pregnancy. However, none of these relative changes in whole 
body BMC were statistically significant between genotypes or between time points.  
 
The lumbar spine has greater contents of trabecular bone in comparison to the whole body. 
Despite this difference, the lumbar spine showed similar absolute and relative changes in BMC 
(Figure 15 and 16). Greater lactational losses in this region were expected based on previous 
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studies showing that more bone is resorbed from the spine as compared to the appendicular 
skeleton. 56 However, excursions are likely blunted due to the enriched diet reducing skeletal 
resorption, and to the artifactual increases in BMC caused by any calcium remaining in the gut 
overlying the spine. As a result, none of these changes reach statistical significance. Both 
genotypes gained BMC during pregnancy as compared to baseline, resorbed bone during 
lactation, and recovered to a value above baseline after weaning.   
 
The hind limb is intermediate between the whole body and lumbar spine in terms of the relative 
content of trabecular bone. Its response to the reproductive periods was largely similar to that 
observed in the whole body and hind limb regions. WT mice do not show any statistically 
significant changes across the reproductive cycle (Figure 17). The Cyp27b1 nulls experience a 
significant increase in hind limb BMC during pregnancy, followed by a significant decrease to 
late lactation and a significant recovery post-weaning. Between genotypes, the Cyp27b1 null has 
a significantly lower baseline value (0.078 ± 0.002 g in WT and 0.059 ± 0.005 g in Cyp27b1-/-). 
Both genotypes have similar BMC during pregnancy (0.094 ± 0.004 g in WT and 0.080 ± 0.005 
g in Cyp27b1-/-), while the greater lactational BMC loss in the nulls compared to WT is 
evidenced by trough points of 0.053 ± 0.004 g and 0.074 ± 0.004 g, respectively. Figure 18 
depicts the relative changes in hind limb BMC. There were no significant differences between 
the genotypes or within genotypes across the reproductive period. It is noted however that 
similar to whole body, the relative 50 % increase in hind limb BMC for Cyp27b1-/- as compared 
to the 20 % increase in WT brought both genotypes to an equal value from baseline to late 
pregnancy.  
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In summary, BMC of Cyp27b1 null females was lower than WT at baseline, increased during 
pregnancy to become equivalent to WT, declined to baseline during lactation, and increased 
post-weaning to a value higher than pre-pregnancy. 
 
3.2.2 Revised analysis of BMC 
Following the previous analysis, it was noted that the drops in BMC during lactation were less 
than expected, especially in the lumbar spine where it normally drops to 15-20 % below baseline 
in WT mice. 56 We wondered if retention of calcium in the gut was obscuring the decline in BMC 
and realized that the mice were eating their calcium-rich feces. Also, prior studies in the Kovacs 
laboratory on Pth null mice indicate that the excursion in BMC is less on the enriched diet as 
compared to the normal diet. 140 Therefore, to reduce potential confounding variables, the mice 
were studied again, this time after not only fasting them but also putting them into clean cages so 
that there would be less of an opportunity for them to eat feces as a rich source of calcium.  
 
These data were also analyzed by comparing both absolute changes (Figure 19) and relative 
changes (Figure 20) in BMC. Similar to the first analysis, Cyp27b1 null mice have significantly 
lower whole body BMC than WT at baseline and late lactation, while none of the relative 
changes in whole body BMC reached statistical significance. Within the lumbar spine, the null 
absolute BMC was lower than WT at baseline and late pregnancy, however not statistically 
significant, again comparable to the first analysis. The hind limb also showed several similarities, 
with the nulls significantly increasing their absolute BMC from baseline to late pregnancy, losing 
BMC during lactation, and recovering post-weaning. However, there were several important 
differences noted from the first data set. Primarily, the decline in lumbar spine BMC during 
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lactation disappeared with the cage changes. Figure 19B shows that the nulls actually experience 
a significant increase in lumbar spine BMC from baseline to late lactation. The excursions that 
occurred in the hind limb region were also much more pronounced than the first analysis. Both 
genotypes showed significant differences between the relative amounts of BMC gained at late 
pregnancy to the relative amount lost at late lactation. The null also lost significantly more BMC 
from baseline to late lactation (-18.67 ± 6.64 %) than the WT (3.49 ± 3.92 %). Lastly, the 
knockout females had a significant increase between the relative BMC lost during lactation to the 
relative BMC gained during recovery.  
 
Of note, the sample sizes for each of the figures are displayed on the x-axis. The sample size 
intended for each genotype using the original methodology and the new methodology of placing 
the mice in clean cages was 12 and 12 for WT and null. However, due to unanticipated deaths 
during delivery of anesthesia for DXA scans and intentional harvesting of mice at late lactation 
in the second methodology for histomorphometry experiments, numbers did not turn out 
consistent across the reproductive cycle. Furthermore, early parturition in both genotypes 
prevented these mice from being available for DXA scans at the time point of late pregnancy, so 
numbers were notably lower at this time point. 
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Figure 12: Whole body BMC in WT and Cyp27b1-/- mice at baseline. Cyp27b1 null mice 
have significantly less BMC than WT at baseline. Values are means ± SE and sample sizes are 
indicated in parentheses. 
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Figure 13: Absolute changes in whole body BMC throughout the reproductive cycle. The 
BMC was significantly reduced in Cyp27b1-/- as compared to WT at baseline and late lactation. 
The null BMC increases significantly from baseline to pregnancy, and decreases significantly at 
late lactation. Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 14: Relative changes in whole body BMC versus baseline throughout the 
reproductive cycle. There were no significant differences between WT and Cyp27b1-/- at any 
time point throughout the reproductive cycle. In general, both genotypes experience BMC 
increases during pregnancy, losses during lactation, and return their BMC values to slightly 
above baseline after weaning. Due to their lower baseline value, Cyp27b1 nulls experience 
greater relative excursions compared to WT. Values are means ± SE and sample sizes are 
indicated in parentheses. 
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Figure 15: Absolute changes in lumbar spine BMC throughout the reproductive cycle. No 
significant difference was noted between either genotype at any time point. Values are means ± 
SE and sample sizes are indicated in parentheses. 
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Figure 16: Relative changes in lumbar spine BMC versus baseline throughout the 
reproductive cycle. There were no significant differences between WT and Cyp27b1-/- at any 
time point throughout the reproductive cycle. The lumbar spine showed the greatest relative 
decrease in BMC during late lactation, and then recovered post-weaning. Values are means ± SE 
and sample sizes are indicated in parentheses. 
 
 
 
 
 
 
 
-­‐30.0%	  
-­‐20.0%	  
-­‐10.0%	  
0.0%	  
10.0%	  
20.0%	  
30.0%	  
40.0%	  
50.0%	  
60.0%	  
R
el
at
iv
e	  
Ch
an
ge
s	  
of
	  B
M
C	  
in
	  L
u
m
b
ar
	  S
p
in
e	  
V
er
su
s	  
B
as
el
in
e	  
(%
)	  
Late	  Pregnancy	  	  	  	  	  	  	  	  	  	  Late	  Lactation 	  Recovery	  
	  	  	  	  	  	  	  	  	  	  	  	  	  (6)	  	  	  	  (9)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (11)	  	  	  	  (11)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (11)	  	  	  	  (11)	  
WT	  NULL	  
	   90	  
	  
Figure 17: Absolute changes in hind limb BMC throughout the reproductive cycle. The 
BMC was significantly reduced in Cyp27b1-/- as compared to WT at baseline and late lactation. 
The null BMC significantly increases from baseline to pregnancy, decreases significantly at late 
lactation, and significantly increases post-weaning to a value higher than what was seen pre-
pregnancy. Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 18: Relative changes in hind limb BMC versus baseline throughout the reproductive 
cycle. There were no significant differences between WT and Cyp27b1-/- at any time point 
throughout the reproductive cycle. The hind limb showed the greatest relative increase in BMC 
during pregnancy, followed by a decline during lactation, and an increase during recovery. 
Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 19: Revised analysis of absolute changes in BMC throughout the reproductive cycle. 
Whole body BMC (A) was significantly lower in Cyp27b1-/- than in WT at baseline and late 
lactation. WT significantly increase BMC from baseline to late pregnancy. In B) lumbar spine, 
null BMC significantly increases from baseline to late lactation. Both genotypes display 
significant increases in hind limb BMC (C) from baseline to late pregnancy, followed by a 
decline in late lactation. Null BMC is significantly lower than WT at late lactation, and increases 
significantly post-weaning. Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 20: Revised analysis of relative changes in BMC versus baseline throughout the 
reproductive cycle. There were no significant differences between WT and null at any time 
point in A) whole body or B) lumbar spine. In C) hind limb, BMC is significantly reduced in 
both genotypes from late pregnancy to late lactation, then increases significantly in the null post-
weaning. The relative change at late lactation in Cyp27b1-/- is significantly reduced in 
comparison to WT. Values are means ± SE and sample sizes are indicated in parentheses. 
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3.3 Mineral assessment 
Mineral analysis of serum and urine was next assessed, as the levels of calcium and phosphorus 
are impacted by delivery from the intestine, bone, kidneys, and parathyroid gland.  
  
3.3.1 Serum and urine total calcium measurement 
Normally, serum calcium concentrations in the mouse do not change throughout the reproductive 
period, and this was the case for WT mice (Figure 21). However, there were significant changes 
in serum calcium concentrations in the null females. Despite the rescue diet, Cyp271 nulls have 
significant hypocalcemia at baseline (1.98 ± 0.03 mmol/L in WT and 1.69 ± 0.12 mmol/L in 
Cyp27b1-/-). Serum calcium levels are rescued during pregnancy and post-weaning recovery, but 
worsened when the dam was lactating (2.07 ± 0.05 mmol/L in WT and 1.11 ± 0.12 mmol/L in 
Cyp27b1-/-).  
 
Urine calcium in the fasted mouse is also normally unchanged throughout the reproductive cycle. 
In this experiment, urine calcium excretion was similar between WT and null mothers (Figure 
22). The mean levels did drop approximately 50 % during lactation from baseline in both 
genotypes, even though statistical significance was not achieved.  
 
To summarize, WT mice displayed constant levels of serum calcium, whereas the Cyp27b1 null 
had hypocalcemia at baseline and late lactation that was rescued by pregnancy and post-weaning 
recovery. Both genotypes had a non-significant decline in urine calcium during lactation. 
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Figure 21: Serum total calcium in WT and Cyp27b1-/- mice throughout the reproductive 
cycle. Cyp27b1 nulls were hypocalcemic at baseline. The serum calcium concentrations 
increased during pregnancy such that it was no different from WT, dropped significantly in the 
null mice during lactation, and gradually improved to equal WT during post-weaning recovery. 
Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 22: Urine total calcium in WT and Cyp27b1-/- mice throughout the reproductive 
cycle. Cyp27b1 null and WT mice had similar urine calcium excretion at all time points 
throughout the reproductive period. Values are means ± SE and sample sizes are indicated in 
parentheses. 
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3.3.2 Serum and urine inorganic phosphorus measurement 
In the normal condition, serum phosphorus increases during mid-lactation due to increased 
skeletal resorption that exceeds the capacity of the kidneys to excrete. Observing the late 
lactation time point rather than mid-lactation will have missed this normal change. In this 
experiment, the WT had constant levels of serum phosphorus throughout the reproductive cycle 
(Figure 23). Cyp27b1 nulls experience a significant decrease in serum phosphorus from baseline 
to late lactation. 
 
In the unfasted mouse, urine phosphorus normally increases during lactation due to the effect of 
PTHrP to promote excretion and due to the increased renal filtered load of phosphorus. These 
changes are more marked at mid-lactation rather than the late lactation time point we measured. 
Findings in this experiment (Figure 24) show that the WT experienced a doubling of urine 
phosphorus during lactation but it did not reach statistical significance. The null also did not 
show any statistically significant changes throughout the reproductive cycle.  
 
In summary, both WT and null siblings show constant levels of serum phosphorus throughout 
reproduction except for a decrease during late lactation in the null. Urine phosphorus increases in 
both genotypes during lactation but does not reach statistical significance. 
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Figure 23: Serum phosphorus in WT and Cyp27b1-/- mice throughout the reproductive 
cycle. There were no significant differences in serum phosphorus levels between both genotypes 
throughout reproduction. Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 24: Urine phosphorus in WT and Cyp27b1-/- mice throughout the reproductive cycle. 
Cyp27b1 null and WT mice had similar urine phosphorus excretion at all time points throughout 
the reproductive period. Values are means ± SE and sample sizes are indicated in parentheses. 
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3.4 Hormone physiology 
Hormonal analysis of serum was performed to gain a better understanding of the physiological 
role in regulating calcium and phosphorus homeostasis and the observed changes to the skeleton 
during reproduction. 
 
3.4.1 Serum PTH 
PTH usually decreases during pregnancy and lactation, and published research reports that PTH 
is normal in Cyp27b1 null mice maintained on the rescue diet. 33,38 WT mice display low values 
during pregnancy and lactation, followed by a doubling post-weaning. Cyp27b1 nulls display 
marked secondary hyperparathyroidism (Figure 25). At baseline, PTH levels are increased (2,815 
±1,292 ng/ml vs. 8.4 ± 3.9 ng/ml), then reduced at pregnancy to a level numerically higher than 
WT but not significantly different. During lactation, PTH increased to 5,500 ± 680 ng/ml, and 
remained high post-weaning.  
 
Since the diet was not changed, it is evidently something about pregnancy alone that caused PTH 
to normalize during pregnancy, and whatever this is disappears during lactation.  
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Figure 25: Serum PTH in WT and Cyp27b1-/- mice throughout the reproductive cycle. 
Cyp27b1 nulls display marked secondary hyperparathyroidism at baseline, lactation and post-
weaning; however, the PTH levels are similar to WT during pregnancy. Values are means ± SE 
and sample sizes are indicated in parentheses. 
 
 
 
 
 
 
 
 
	  102	  
3.4.2 Serum calcitriol 
In rodents, calcitriol levels normally increase during pregnancy and lactation. Serum calcitriol 
rose >5-fold in WT mice during pregnancy, and remained high during lactation (Figure 26). This 
increase was absent in Cyp27b1 nulls. The null calcitriol level is lower at baseline than WT 
(12.18 ± 1.04 pmol/L vs. 46.41 ± 13.81 pmol/L), although not statistically significant. This value 
of 12 pmol/L is indistinguishable from the detection limit of human sera (6 pmol/L) and may 
represent the detection limit for mouse sera under these conditions (detection limit in mouse 
serum has not been reported). The null baseline value then showed an apparent but statistically 
non-significant increase during pregnancy.  
 
In summary, WT mice experienced the expected several-fold increase in calcitriol during 
pregnancy and lactation. In contrast, the nulls had low values throughout the reproductive cycle 
that increased non-significantly during pregnancy.  
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Figure 26: Serum calcitriol in WT and Cyp27b1-/- mice throughout the reproductive cycle. 
Cyp27b1-/- mice have a trend towards lower calcitriol levels at baseline than WT. Serum 
calcitriol rose >5 fold in WT mice during pregnancy while this increase is absent in the nulls. 
The knockout mice also display low calcitriol levels at late lactation while the WT remains high. 
Values are means ± SE and sample sizes are indicated in parentheses. 
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3.4.3 Serum FGF23 
FGF23 inhibits calcitriol synthesis, and calcitriol in turn stimulates FGF23 synthesis. It was 
therefore expected that FGF23 levels would increase during pregnancy in the WT mouse, while 
the knockout would be deficient throughout reproduction. A significant increase in FGF23 was 
observed in the WT during pregnancy, followed by a significant decrease in late lactation and 
recovery 1 (Figure 27). Basal FGF23 was lower in the Cyp27b1 null and the rise during 
pregnancy was significantly blunted (Figure 27). Between genotypes, FGF23 levels are 
significantly lower in the Cyp27b1-/- than the WT at late pregnancy (196.48 ± 51.55 pg/ml vs. 
696.56 ± 34.99 pg/ml), late lactation (38.91 ± 24.18 pg/ml vs. 347.71 ± 110.35 pg/ml), and 
recovery 1 (12.85 ± 4.19 pg/ml vs. 306.09 ± 60.37 pg/ml). 
 
In summary, FGF23 levels were increased in WT during pregnancy, while the rise was blunted 
in the Cyp27b1 null. 
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Figure 27: Serum FGF23 in WT and Cyp27b1-/- mice throughout the reproductive cycle. 
FGF23 was increased in WT during pregnancy. In the Cyp27b1 null, basal FGF23 was lower and 
the rise during pregnancy was not significant. Values are means ± SE and sample sizes are 
indicated in parentheses. 
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3.5 Markers of bone turnover 
The P1NP serum biomarker and DPD urine biomarker were measured to indicate changes in the 
rate of bone formation and resorption, respectively. 
 
3.5.1 Serum P1NP 
P1NP levels are not significantly changed in WT throughout the reproductive cycle, however 
show a non-significant decrease and increase during pregnancy and post-weaning, respectively. 
This pattern is mirrored in the P1NP levels of the null siblings. The peak of P1NP at recovery 1 
in Cyp27b1-/- is significantly greater than its values at late lactation, late pregnancy, and baseline. 
Between genotypes, P1NP is significantly increased in the Cyp27b1 null over WT at recovery 1 
(44.12 ± 4.56 ng/ml in WT and 173.68 ± 28.14 ng/ml in Cyp27b1-/-), indicative of increased bone 
formation, but no different from WT at the earlier time points (Figure 28).  
 
Both genotypes show a general trend of decreased bone formation during pregnancy, followed 
by increased bone formation during lactation and recovery. This increase is greater and reaches 
statistical significance in the Cyp27b1 null. 
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Figure 28: Serum P1NP in WT and Cyp27b1-/- mice throughout the reproductive cycle. The 
bone formation marker P1NP rose significantly during post-weaning recovery in the Cyp27b1 
null. WT showed the same pattern of serum P1NP changes during the reproductive period, 
however these changes were not significant. Values are means ± SE and sample sizes are 
indicated in parentheses. 
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3.5.2 Urine DPD 
DPD normally increases early to mid lactation, and then subsides to normal by late lactation. WT 
mice are consistent with normal at baseline and late pregnancy; however, they maintain 
increased bone resorption at the end of lactation (Figure 29). Cyp27b1 null mice have a trend of 
decreased bone resorption at late pregnancy and late lactation. Between genotypes, the null has 
higher DPD than WT at every time point, although this does reach statistical significance.  
 
No significant differences are noted between the urine DPD levels of WT and Cyp27b1 null mice 
at any time point. 
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Figure 29: Urine DPD in WT and Cyp27b1-/- mice throughout the reproductive cycle. WT 
and Cyp27b1-/- mice do not have any significant differences between them at any time point. 
Values are means ± SE and sample sizes are indicated in parentheses. 
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3.6 Micro computed tomography 
Micro-computed tomography was used to assess skeletal microarchitecture on Cyp27b1 null and 
WT femurs. Although DXA provides a measure of bone mineralization, this is only 2-
dimensional and no information is provided on thickness or structure of the skeleton. Further, 
interference from calcium outside the skeleton may have falsely increased measurements of the 
mineral content. Analyzing the bone microarchitecture could determine if there were any 
alterations in the trabecular or cortical structure between the two genotypes.  
 
Throughout reproduction and in comparison to virgin controls age-matched to mice harvested at 
the recovery 4 time point (Figure 9), there were several notable micro architectural differences in 
the femora within and between genotypes. It is noted that the late pregnancy time point is not 
represented, so comparisons are made between the time points of baseline and late lactation for 
all the analyses. Femoral length remains constant in the WT mice throughout reproduction and 
the virgin controls have similar measurements (Figure 30). In the null animals, there appears to 
be an effect of recovery whereby bone length is significantly improved at recovery 1 and 
recovery 4 as compared to baseline. The null virgin controls display a femoral length in between 
that of baseline and late lactation. No statistically significant differences in femoral length were 
found between WT and Cyp27b1 null mice.  
 
Trabecular bone volume shows a pattern of lower BV/TV in late lactation, recovery 1, and 
recovery 4 compared to baseline and the virgin controls in WT mice (Figure 31). Surprisingly, 
the WT mice have no detectable difference in trabecular bone volume between late lactation and 
recovery 4. This effect of lactation and recovery is also the same in null siblings. Between 
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genotypes there are no significant differences. The changes in trabecular bone volume are mostly 
mirrored by the alterations in trabecular number (Figure 34). Both WT and null display reduced 
trabecular number at late lactation, recovery 1, and recovery 4 in comparison to the virgin 
controls, with no differences between genotypes. Trabecular separation is in line with the 
previous results, showing the opposing pattern as trabecular bone volume and trabecular number 
(Figure 32). WT mice display a trend of increased separation at late lactation, recovery 1, and 
recovery 4 compared to baseline and virgin controls, although this is not statistically significant. 
Cyp27b1 null show this same pattern, reaching statistical significance in comparison to the virgin 
controls. Between genotypes there are no significant differences. 
 
The changes in trabecular thickness are separate from the aforementioned adaptations, with only 
the WT experiencing a significant decrease from baseline to late lactation (Figure 33). There is a 
trend towards increased trabecular thickness during recovery, however this does not reach 
statistical significance nor the thickness measured pre-pregnancy. The femoral trabecular 
thickness of virgin controls is also similar to the recovery values. The Cyp27b1 nulls show a 
similar pattern to WT, however none of the changes measured are significant. There are also no 
differences measured between genotypes. 
 
Looking next at the changes to cortical bone, it can be seen that the WT have significantly 
reduced cortical thickness at recovery 1 and recovery 4 in comparison to virgin controls (Figure 
35). The nulls experience even greater loss of cortical thickness but fully recover this by the 
recovery 4 time point. The null virgin controls have the highest cortical thickness; significantly 
increased in comparison to all the reproductive time points measured. Further evidence for the 
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loss of cortical bone in the nulls is shown by their significantly reduced thickness in comparison 
to WT at late lactation and recovery 1. Cortical area remains constant in the WT throughout 
reproduction and is equal to the femoral cortical area of virgin controls (Figure 36). The 
knockout mice show a trend of reduced cortical thickness at late lactation and recovery 1, 
followed by improvement at recovery 4 to a value higher than pre-pregnancy; however, this is 
not statistically significant. In the null virgin control, cortical area is significantly greater than all 
the reproductive time points measured. Between genotypes, cortical area is lesser in the null than 
their WT siblings at late lactation.   
 
Marrow area does not change throughout reproduction in WT mice, although the virgin controls 
have a small but non-significant decrease compared to the earlier time points (Figure 37). 
Cyp27b1 null mice show a significant increase in marrow area at late lactation and recovery 1 in 
comparison to the virgin controls, corroborating the loss of cortical bone seen in the changes to 
cortical thickness and area. No significant differences are present between genotypes. Finally, 
endocortical perimeter (Figure 38) and periosteal perimeter (Figure 39) are not modified by 
reproduction, and there are no significant differences noted within or between genotypes. 
 
To summarize, the assessment of skeletal architecture using micro-computed tomography 
revealed a significant increase in femoral length of the nulls after a reproductive cycle, 
permanent loss of trabecular bone in WT and null mice, and loss followed by recovery of cortical 
bone in the nulls. 
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Figure 30: Femoral length of WT and Cyp27b1-/- mice throughout the reproductive cycle. 
Null mice have improved bone length at recovery 1 and recovery 4 compared to baseline. Values 
are means ± SE and sample sizes are indicated in parentheses. 
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Figure 31: Percent femoral bone volume of WT and Cyp27b1-/- mice throughout the 
reproductive cycle. Both genotypes have lower BV/TV in late lactation as compared to the 
virgin controls. The knockout mice also have reduced bone volume in comparison to baseline, 
while the WT show a decrease from baseline to recovery 4 such that the femurs have 
significantly lower volume compared to the virgin age-matched controls. Values are means ± SE 
and sample sizes are indicated in parentheses. 
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Figure 32: Femoral trabecular separation of WT and Cyp27b1-/- mice throughout the 
reproductive cycle. Null mice have increased trabecular separation at late lactation, recovery 1, 
and recovery 4 as compared to the virgin controls. Values are means ± SE and sample sizes are 
indicated in parentheses. 
 
 
	  
Figure 33: Femoral trabecular thickness of WT and Cyp27b1-/- mice throughout the 
reproductive cycle. WT mice have reduced trabecular thickness from baseline to late lactation. 
Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 34: Femoral trabecular number of WT and Cyp27b1-/- mice throughout the 
reproductive cycle. Both genotyes display reduced trabecular number at late lactation, recovery 
1, and recovery 4 as compared to virgin controls. Values are means ± SE and sample sizes are 
indicated in parentheses. 
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Figure 35: Femoral cortical thickness of WT and Cyp27b1-/- mice throughout the 
reproductive cycle. WT mice have reduced cortical thickness at recovery 1 and recovery 4 in 
comparison to virgin controls. Null mice have reduced cortical thickness in comparison to virgin 
controls at all time points measured. Null cortical thickness is lesser than WT at late lactation 
and recovery 1. Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 36: Femoral cortical area of WT and Cyp27b1-/- mice throughout the reproductive 
cycle. Cortical area is reduced compared to virgin controls at all time points in the null. The 
knockout mice also have lesser cortical area than WT at late lactation. Values are means ± SE 
and sample sizes are indicated in parentheses. 
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Figure 37: Femoral marrow area of WT and Cyp27b1-/- mice throughout the reproductive 
cycle. Marrow area is increased compared to virgin controls at late lactation and recovery 1 in 
the null. Values are means ± SE and sample sizes are indicated in parentheses. 
 
	  
Figure 38: Femoral endocortical perimeter of WT and Cyp27b1-/- mice throughout the 
reproductive cycle. No significant differences were measured at any time point between or 
within genotypes. Values are means ± SE and sample sizes are indicated in parentheses. 
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Figure 39: Femoral periosteal perimeter of WT and Cyp27b1-/- mice throughout the 
reproductive cycle. No significant differences were measured at any time point between or 
within genotypes. Values are means ± SE and sample sizes are indicated in parentheses. 
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3.7 3-Point bend test 
A standard 3-point bend test was performed to assess the changes to cortical bone strength 
throughout the reproductive period. Tibias from normal and knockout mice were used to assess 
this at baseline, late lactation, recovery 1, and recovery 4. It was predicted that there would be 
decreased bone strength during lactation based on our results depicting BMC loss and µCT 
changes in trabecular and cortical parameters of the femora. BMC increases and improved 
cortical parameters then predict that there would be improved bone strength after recovery. As 
expected, Cyp27b1 null and WT tibias have weaker bone at late lactation, which recovers fully 
by recovery 4 (Figure 40 to 43).  
 
The ultimate load of force required to break tibias in WT was significantly decreased from 
baseline to late lactation, then significantly increased by recovery 4 (Figure 40). Cyp27b1 null 
tibia take longer to regain their strength, displaying significantly reduced force required to break 
at late lactation and recovery 1 in comparison to baseline and recovery 4. The difference in speed 
of recovery is further evidenced by the lower ultimate load in the null at recovery 1 in 
comparison to WT (0.82 ± 0.05 gf vs. 1.86 ± 0.09 gf).  
 
The significant changes seen in energy absorption (Figure 43) mirror those of the ultimate load 
of force required to break tibias. WT mice absorbed less energy prior to breakage at late lactation 
compared to baseline, which then increased by recovery 4. Cyp27b1 null tibia show reduced 
energy absorbed from baseline to late lactation and recovery 1, then an increase by recovery 4. 
Between genotypes, Cyp27b1 null shows reduced energy absorption prior to breakage compared 
to WT at recovery 1, confirming the increased length of time for strength recovery. 
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Tibial stiffness remains relatively constant in the WT throughout reproduction (Figure 42). 
Consistent with the indication of weaker bone in null tibia at recovery 1, knockout tibia display 
reduced stiffness in comparison to their baseline value (4.29 ± 0.38 gf/mm vs. 7.89 ± 0.50 
gf/mm). The null also has reduced stiffness at recovery 1 in comparison to WT (8.89 ± 0.36 
gf/mm).  
 
Displacement of bone from its starting position prior to breakage is another measure provided by 
the by 3-point bend test and is an inverse measure of cortical bone strength. WT mice have 
constant displacement before tibial breakage throughout the reproductive cycle (Figure 41). In 
the null, displacement is significantly increased at late lactation and recovery 1 compared to 
recovery 4. Between genotypes, displacement is higher in the null at recovery 1 (0.88 ± 0.08 µm) 
and recovery 4 (0.63 ± 0.08 µm) as compared to WT (0.54 ± 0.05 µm at recovery 1 and 0.55 ± 
0.08 µm at recovery 4) (Figure 41).  
 
These results show that in both WT and Cyp27b1 mice, cortical bone strength decreases during 
lactation and increases post-weaning, consistent with bone loss followed by recovery and the 
previous DXA and cortical µCT data. A vertebral crush test is needed to assess trabecular 
parameters. 
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Figure 40: Ultimate load until failure using a standard 3-point bend test fixture throughout 
the reproductive cycle. Ultimate load required to cause tibia breakage showed a significant 
decrease from baseline to late lactation in both WT and Cyp27b1 null mice, which significantly 
increased in both genotypes by recovery 4. Cyp27b1 null tibias also required significantly 
reduced load to cause breakage at recovery 1 in comparison to WT. Values are means ± SE and 
sample sizes are indicated in parentheses. 
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Figure 41: Tibial displacement before breakage using a standard 3-point bend test fixture 
throughout the reproductive cycle. Null tibias display significantly increased displacement 
before breakage at Recovery 1 and Recovery 4 in comparison to WT. This distance before 
breakage is also significantly reduced at Recovery 4 in comparison to Recovery 1 and Late 
Lactation in the Cyp27b1 null. Values are means ± SE and sample sizes are indicated in 
parentheses. 
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Figure 42: Tibial stiffness using a standard 3-point bend test fixture throughout the 
reproductive cycle. Cyp27b1 null tibiae have significantly reduced stiffness at Recovery 1 in 
comparison to baseline. There is also significantly reduced stiffness in the null tibia in 
comparison to WT at Recovery 1. Values are means ± SE and sample sizes are indicated in 
parentheses. 
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Figure 43: Energy absorbed by tibias using a standard 3-point bend test fixture throughout 
the reproductive cycle. Both Cyp27b1 null and WT tibia absorbed significantly less energy 
prior to breakage at Late Lactation in comparison to Baseline, followed by a significant increase 
to Recovery 4. Null tibia recover this energy absorption later than WT, displaying significantly 
less energy absorbed at Recovery 1 in comparison to WT, and in comparison to its baseline 
value. Values are means ± SE and sample sizes are indicated in parentheses. 
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3.8 Intestinal calcium absorption 
Normally, intestinal calcium absorption doubles during pregnancy in humans and rodents. This 
increase has been assumed to be caused by the increase in calcitriol; however, vitamin D 
deficient animals and VDR null mice still upregulate intestinal calcium absorption during 
pregnancy. 45Ca injection via gastric gavage was performed and blood 45Ca levels were analyzed 
as an indirect measure of intestinal calcium absorption. This was necessary to determine if 
Cyp27b1 null mice have reduced absorption at baseline compared to the WT mice, and if despite 
the absence of calcitriol, null mice were able to upregulate intestinal calcium absorption during 
pregnancy and post-weaning. In this experiment, the amount of radioactivity absorbed into the 
bloodstream was found to be constant across baseline, late pregnancy, and recovery 1 in the WT 
(Figure 44). In the Cyp27b1 null, the blood levels of radioactivity were significantly higher at 
late pregnancy than recovery 1. No significant differences between genotypes were measured. 
 
Cyp27b1 null mice have increased instestinal calcium absorption during pregnancy, whereas WT 
mice had similar intestinal calcium absorption at all time points throughout the reproductive 
period. 
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Figure 44: Radioactivity in 100 µl whole blood after injection of 45Ca throughout the 
reproductive cycle. The Cyp27b1 null had significantly higher radioactivity absorbed into 
circulation at late pregnancy compared to recovery 1. There were no significant differences in 
blood radioactivity between the genotypes at any time point. Values are means ± SE and sample 
sizes are indicated in parentheses. 
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IV. DISCUSSION 
Calcitriol is the active form of vitamin D and plays a critical role in regulating calcium and bone 
metabolism in the child and adult, primarily through its actions to increase intestinal calcium 
absorption. Previous studies suggest that vitamin D and VDR are not required to regulate the 
adaptations to bone and intestines throughout reproduction. 27,120,147,151,152,154 However, these 
studies had several limitations including variable extent of skeletal recovery in vitamin D 
deficient rats, and uncertainty as to whether the very high calcitriol concentrations in the 
circulation of Vdr null mice are biologically active or not. It is possible that calcitriol is acting 
through non-genomic receptors to invoke the regulatory systems during pregnancy, lactation, and 
post-weaning recovery. 128,147,208-212 Our hypothesis was that calcitriol is required for 
upregulation of intestinal calcium absorption during pregnancy and post-weaning, and to enable 
normal recovery of bone mass post-weaning. If so, the high levels of circulating calcitriol would 
have enabled the Vdr null to have a normal skeletal and intestinal response during the 
reproductive cycle; therefore, we predict that inhibition of calcitriol synthesis would lead to a 
different bone and intestinal phenotype than loss of Vdr protein, with a reduced potential for 
BMC recovery after the demands of pregnancy and lactation. We tested this hypothesis by 
examining BMC and other bone phenotypes, biochemical measurements, and intestinal calcium 
absorption of calcitriol-deficient Cyp27b1 null female mice during one reproductive cycle with 
matched litter sizes.  
 
Compared to WT, at baseline Cyp27b1 nulls were hypocalcemic with markedly increased PTH 
and 30 % lower BMC; µCT displays a trend of reduced femoral length, cortical thickness, and 
cortical area. During pregnancy in Cyp27b1 nulls, serum calcium increased to normal values, 
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PTH substantially reduced to approach WT values, and BMC increased 45 % so that all values 
became equivalent to WT. During lactation in Cyp27b1 nulls, serum calcium dropped, PTH 
increased to similar values seen prior to pregnancy, BMC declined to baseline, and cortical bone 
strength decreased; µCT confirmed extensive endocortical resorption in addition to loss of 
trabecular number and thickness. During post-weaning in Cyp27b1 nulls, serum calcium 
normalized again, PTH remained at very high levels, BMC increased to 40 % above pre-
pregnancy values, and cortical bone strength recovered to pre-pregnancy levels. Although there 
was recovery of cortical bone, µCT shows that both WT and Cyp27b1 nulls still had reductions 
in femoral trabecular bone volume at 4 wks post-weaning. Whether these changes would resolve 
or persist is presently unknown. In comparison to WT mice, the Cyp27b1 null females display 
low (probably undetectable) levels of calcitriol and significantly lower levels of FGF23 
throughout the reproductive cycle. Blood 45Ca levels indicative of intestinal calcium absorption 
were increased during pregnancy in the Cyp27b1 null, while WT mice displayed constant levels 
throughout the reproductive period.  
 
4.1 Influence of the rescue diet on baseline phenotype 
In order to support fertility, Cyp27b1 null females and WT females derived from heterozygous 
Cyp27b1+/- breeders were fed a 2 % calcium “rescue” diet from the time of weaning. At baseline, 
Cyp27b1 null mice have reduced BMC, reduced femoral cortical thickness and area, 
hypocalcemia, and marked secondary hyperparathyroidism. These changes occur despite the 
“rescue diet”, suggesting that the diet does not maintain normal mineral homeostasis and bone 
mass in mice that have reached 10 wks of age. This is largely in contrast to previous literature. 
33,38,130 Dardenne studied the same model we used, and found that the rescue diet corrected 
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hypocalcemia and secondary hyperparathyroidism, and histomorphometry confirmed that rickets 
and osteomalacia was cured. 33 There are a number of reasons as to why our results may be in 
contrast to the rescued rachitic phenotype shown by these authors. Primarily, our mice were 
studied at an older age, beginning at 10 wks as compared to 8.5 wks. Also, some of the 
methodologies used to analyze the bone and mineral metabolism were different. Dardenne 
performed serum biochemical measurements of calcium and phosphorus using a Monarch 
automated analyzer, whereas we utilized a spectrophotometer. Histomorphometry was used 
rather than µCT to analyze the microarchitecture of bone, and they did not measure BMC in any 
way. Moreover, the model went through some years of subsequent inbreeding in their facility 
before being sent to us, and so the mice may have drifted genetically from what was originally 
created. Although we backcrossed the mice into C57BL/6 as soon as we received them, the mice 
we studied may be genetically distinct from the original strain that Dardenne studied.  
 
Two other groups used a different and independently created Cyp27b1 null model, and found 
that the enriched diet fully rescued or prevented the rachitic phenotype. As explained in section 
1.1.11.5, both Panda and Sun used a model that had the Cyp27b1 gene fully ablated by deletion 
of both the hormone binding domain encoded by exons 6 and 7, and the heme binding domain 
encoded by exon 8. 38,130 In contrast, our model (the same one originally reported by Dardenne) 
only had exon 8 deleted, with part of introns 7 and 8 (Figure 5). These differences in engineering 
conceivably could have led to the differences seen in serum calcium, phosphorus, and PTH. 
There were also several differences in their methodologies, including an autoanalyzer for serum 
calcium and phosphorus, and computer-assisted image analysis of hematoxylin and eosin 
staining or histochemical staining rather than µCT. However, Panda did find several skeletal 
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alterations with reduced trabecular volume, reduced osteoid volume, and reduced osteoblast 
number, similar to our findings. Thus, these changes in bone volumes and osteoblast numbers 
suggest that the enriched diet did not fully prevent the rachitic phenotype. These mice were 
studied at 15 wks. They suggest that it is possible that the mice become more dependent on 
calcitriol with age, and that prolonged exposure to the diet results in skeletal abnormalities. 
Furthermore, although Panda and Sun studied pairs of female siblings, only Sun generated the 
colony and experimental mice by mating heterozygous males and females together. Panda 
maintained their colony by mating null males to heterozygous females, which could have created 
null mice that drifted genetically from WT. These mice were also maintained on a mixed genetic 
background with contributions from C57BL/6 and BALB/c strains, which may have resulted in 
considerable variation in the mouse phenotype. 222,223  
 
To summarize, Dardenne, Panda, and Sun all found normal levels of serum calcium and 
phosphorus in Cyp27b1 mice on the rescue diet, with no or modest changes to the skeleton. The 
most striking difference was the PTH level, which was equivalent to WT levels on the rescue 
diet as measured by both Dardenne and Panda, whereas our studies show significant secondary 
hyperparathyroidism. Dardenne used the same mouse intact PTH ELISA kit as the one we 
employed (Immunotopics), whereas Panda used a two-site immunoradiometric assay (IRMA) 
(Immunotopics). It is also critical to note that Sun did not measure PTH, and it is therefore 
possible that the level could have been increased. The diet may be ruled out as a potential cause 
for these differences, as the same manufacturer and formula was used in the previous studies 
(TD.96348, Teklad) as was in ours, except ours had a green colour coding (TD.94112, Teklad). 
Our studies analyzed different details, using DXA as reflective of mineralization and µCT for 
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structural information, in comparison to the histomorphometry or image analysis of staining. 
Histomorphometry would have shown increased surface area and thickness of unmineralized 
osteoid, which is pathognomonic of rickets. A limitation of histomorphometry, however, is that it 
examines a sample (one or a few sections) of the tibia or femur, or the vertebrae, and assumes 
that the rest of the bone has the same structure. MicroCT examines all of the bone in the region 
of interest, mitigating the error from selective sampling. We still plan to do histomorphometry, 
but for the purposes of completing a Masters degree, the work is beyond the time possible. 
Nonetheless, we may have detected a phenotype that slowly emerges as the mice get older that 
Dardenne stopped too early to detect, and numerous other reasons may compensate for the 
differences seen with Panda and Sun. From our results, the diet does not normalize mineral and 
skeletal homeostasis because serum calcium, PTH, and bone mass are not normal by 10-12 wks 
of age. Age-related changes in the permeability of the intestines to passive calcium absorption 
may mean that the rescue diet becomes insufficient with age, or it could be that there is still a 
role for calcitriol in older mice to regulate bone metabolism directly or influence intestinal 
calcium absorption independent of diet.  
	  	  	  	   
4.2 Adaptations to reproduction 
A variety of experiments were conducted to determine if the loss of calcitriol synthesis would 
impair intestinal calcium absorption and skeletal metabolism despite the presence of the enriched 
calcium diet. Contrary to our initial hypothesis and to their impaired mineral homeostasis and 
reduced bone mass at baseline, the Cyp27b1 null females had significantly improved bone 
metabolism (BMC and cortical bone strength) post-weaning and efficiency of intestinal calcium 
absorption was increased during pregnancy. We expected to be studying Cyp27b1 null females 
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that were phenotypically indistinguishable from WT females because of use of the rescue diet, 
but instead the mice had several deficits at baseline. Having lower BMC, reduced femoral 
cortical thickness and area, hypocalcemia and secondary hyperparathyroidism, may have actually 
been more beneficial to the research because it revealed that pregnancy and post-weaning caused 
improvements in bone mass and mineral homeostasis independent of the constant presence of the 
rescue diet. In fact, this turned out to be the case as pregnancy improved certain parameters, 
including serum calcium, BMC, and secondary hyperparathyroidism.   
 
4.2.1 Cyp27b1 null response to pregnancy 
Pregnancy is characterized by significant demand on the mother to provide calcium for fetal 
development. In my experiments, it was observed that pregnancy improved the Cyp27b1 null 
female dam. BMC increased during pregnancy, such that the low bone mass of the Cyp27b1 null 
females relative to WT females at baseline became equal to WT females during pregnancy. 
Hypocalcemia and secondary hyperparathyroidism were also rescued at this time point. This 
likely indicates increased intestinal calcium absorption via calcitriol-independent mechanisms 
that resulted in mineralization of osteoid and suppression of PTH release. The 45Ca in blood 
increased during pregnancy in the Cyp27b1 null compared to baseline, suggesting an 
improvement in intestinal calcium absorption during pregnancy. These results are very similar to 
what was seen in the Vdr null female mice; despite the absence of a functional receptor for 
calcitriol, the Vdr null females also showed BMC increases of 58 % and a reduction in PTH 
during pregnancy. 147 The Vdr nulls were studied using a different methodology for intestinal 
calcium absorption (duodenal loop method), but did show a significant increase from baseline to 
pregnancy.  
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4.2.2 Cyp27b1 null response to lactation 
During lactation, milk production places further demands on the mother’s calcium resources. In 
mice, the dam mitigates against the greater demand by increasing intestinal calcium absorption 
and resorption of the skeleton. Humans accomplish this by relying on increased resorption of the 
skeleton, while intestinal calcium absorption is normal. Reducing the calcium intake of mice 
increases skeletal resorption whereas increasing calcium intake has the opposite effect. Cyp27b1 
null female mice lost a significant amount of bone in the hind limb as compared to pregnancy 
using the revised analysis of BMC. Both the first and revised analysis also showed that the null 
had significantly lower BMC compared to WT at this time in whole body and hind limb. These 
losses were actually greater than what the Vdr nulls experienced, as their BMC at late lactation 
was equal to WT. 147 The 3-point bend test corroborated a loss of cortical bone strength in the 
null tibiae during this time. µCT results provide further insight into the loss of bone during 
lactation. The adaptations to trabecular bone are largely the same between genotypes, with both 
displaying lower bone volume, reduced trabecular number, and increased trabecular separation 
during this time. However, the Cyp27b1 null female mice experienced greater changes to cortical 
bone than their WT counterparts. Loss of calcitriol results in significantly lower cortical 
thickness and cortical area. This may suggest that calcitriol provides a protective effect on 
cortical bone during lactation. The significantly increased marrow area and trend toward 
increased endocortical perimeter indicates that the changes to cortical bone occur largely due to 
endocortical resorption in these areas rather than a reduction in periosteal apposition. 
 
One possible explanation for the BMC, cortical bone strength, and structural changes in the 
skeleton of the Cyp27b1 null female mice is that Cyp27b1 null mice have had less calcium 
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absorbed through the diet, so they resorb more bone in compensation. It is possible that intestinal 
calcium absorption was not upregulated during lactation. Alternatively, there could have been no 
difference in intestinal calcium absorption, but that loss of calcitriol directly leads to increased 
PTH secretion and consequently, bone resorption. Loss of calcitriol could also have affected 
milk production, creating an increased drain on the supply that results in compensatory bone 
resorption. Measurement of the calcium content of milk in Cyp27b1 null and WT mice could 
determine if this is the case or not. 
 
Despite significant resorption of bone seen in the knockout during lactation, Cyp27b1 nulls 
became markedly hypocalcemic. Secondary hyperparathyroidism accompanied the decrease in 
serum calcium. Urine calcium excretion decreased in both genotypes throughout lactation, 
suggesting that calcium was not being lost in the urine but rather being used to produce milk. 
These results are indicative of the maternal challenge to provide adequate mineral to their 
growing pups. Serum phosphorus also decreased in the null at late lactation, however, a non-
significant increase of the mineral was measured in the urine. WT dams are carrying WT and 
heterozygous pups while Cyp27b1 null dams are carrying heterozygous and null pups. Both 
dams carried similar numbers of pups, but the possibility that the different genotypes of the pups 
somehow influenced the maternal responses to pregnancy and lactation has not been excluded. 
The dams will consume their own urine and feces, which is a source of calcium, and 
unavoidable. Since WT and Cyp27b1 null dams had similar urine calcium excretion, and 
consumed the same diet and water, the calcium available to consume was therefore similar 
between the two groups. 
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Intestinal calcium absorption was not measured during lactation, however it is critical to know 
whether it is reduced in the Cyp27b1 nulls at this time point. If so, it could imply that placental 
factors, such as placental lactogen, are responsible for upregulating intestinal calcium absorption 
during pregnancy, and that these factors are lost during delivery. However if intestinal calcium 
absorption is upregulated equal to WT, then loss of calcitriol may be leading to effects on milk 
production, parathyroid glands, or bone loss independent of intestinal calcium delivery. A future 
direction for this project is to measure intestinal calcium absorption and milk calcium content in 
the WT and Cyp27b1 null females during lactation, to address this specific hypothesis.  
 
4.2.3 Cyp27b1 null response to post-weaning recovery  
Following the 3 wks of lactation, there is clear evidence in Cyp27b1 null females for 
improvements in bone and mineral metabolism despite the absence of calcitriol. An increase in 
BMC was measured by DXA in both genotypes, to a value higher than what was measured at 
baseline.  This recovery of bone mass was measured in whole body, lumbar spine, and hind limb 
in both the initial data set and the revised protocol with mice placed in clean cages, to avoid the 
confounding factor of coprophagia during the pre-assay fasting period. Collectively, this likely 
indicates calcitriol-independent stimulation of new bone formation. This is similar to the 
recovery seen in Vdr null female mice, which also showed increased BMC to a value higher than 
pre-pregnancy baseline. 147. MicroCT suggests that there may also be a boost of longitudinal 
growth in the nulls during this time. Cortical bone increased in both genotypes, as evidenced by 
the increase in cortical thickness and cortical area. However, the changes to trabecular bone did 
not recover within the 4 wks of study, as shown by the consistent decrease in bone volume at the 
fourth wk post-weaning. These site-specific changes in bone microarchitecture may be explained 
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by the properties of long bones. Similar to previous research, our results suggest that long bones 
may have lasting alterations in trabecular structure after lactation. 156,201 It has been proposed that 
different skeletal sites may resorb bone using different mechanisms. 201 The rods and plates of 
long bones are perforated and broken during lactation, impairing the ability to restore 
microarchitecture. Conversely, bone loss in the spine may occur through thinning and perforation 
of trabecular plates, allowing for retained connectivity and a filling of the perforations after 
lactation. Performing microCT on the spine would help provide further evidence of this theory, 
and is a future direction for this project. Despite trabecular bone not recovering post-weaning, 
the 3-point bend test shows a gain in bone strength in the null female tibiae from late lactation to 
recovery. This test is largely a measurement of cortical bone properties, which did recover to 
normal. Thus, long-term bone strength may be normal after lactation in the Cyp27b1 null female 
because of recovery of cortical bone parameters and despite permanent changes in trabecular 
architecture.  
 
In contrast to the hypocalcemia that developed during lactation, serum minerals normalized 
during the post-weaning interval, with calcium and phosphorus being equal between the 2 
maternal genotypes. The blood 45Ca experiments further suggest that intestinal calcium 
absorption is equivalent to WT post-weaning despite the absence of calcitriol. It may be 
suggested that intestinal calcium absorption is maintained by the influence of other hormones 
when calcitriol is absent. An alternative explanation is that intestinal calcium absorption was 
similar during both lactation and recovery, and that the main problem for the null mice was the 
drain of calcium into milk. Shutting off milk production may have allowed serum calcium to 
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normalize and facilitate bone recovery without implying any change to the rate of intestinal 
calcium absorption. Again, measuring the calcium content of milk should prove informative. 
 
Of interest, PTH still remained significantly higher in the Cyp27b1 nulls as compared to WT at 
the recovery 1 time point. Serum calcium was no different between WT and null 1 wk following 
weaning; however, the levels continued to rise in the null until the fourth wk. It is possible that 
PTH may have normalized in the null after 4 wks post-weaning, or it could also be the case that 
hyperparathyroidism is a persistent mechanism to compensate for the loss of calcitriol. Perhaps 
the unknown factors that helped the Cyp27b1 null mice during pregnancy were wearing off, 
consequently reverting to the baseline state of elevated PTH. This may include intestinal calcium 
absorption dropping back to lower values. In the long run, such high PTH levels will be 
deleterious to bone.10 
 
Taking into consideration all of the changes in PTH levels measured throughout the reproductive 
cycle, it suggests that pregnancy is a key time frame in which calcitriol-independent alterations 
in bone metabolism occur which rescue the null. During lactation, the loss of calcitriol may 
compromise the Cyp27b1 null mice to resorb more bone and lose proportionately more bone 
strength. The recovery of bone mass during the post-weaning interval is also indicative of 
temporary calcitriol-independent effects. After all, the Cyp27b1 nulls have low bone mass at 
baseline but are increasing their bone mass significantly during post-weaning. Something is 
clearly different about the post-weaning interval (with active bone formation occurring) as 
compared to pre-pregnancy (when bone mass was reduced compared to WT). 
 
	  140	  
4.3 Bone mineral content 
BMC was analyzed using two different methodologies; in the first method mice were fasted 
overnight and left in original cages to be scanned the following day, and in the second method 
mice were changed to new cages and similarly fasted overnight. Both analysis strategies showed 
that BMC of Cyp27b1 null females was lower than WT at baseline, increased during pregnancy 
to become equivalent to WT, declined to baseline during lactation, and increased post-weaning 
to a value higher than pre-pregnancy. The revised analysis was performed because we noticed 
that the drops in BMC during lactation were less than expected, especially in the lumbar spine, 
and wondered if this was due to retention of calcium in the gut from the mice eating their 
calcium-rich feces. Rather, the revised method showed reduced losses in the lumbar spine during 
lactation, and greater losses in the hind limb. If coprophagia was really having an effect on the 
BMC, it was expected that placing mice into clean cages would have exaggerated the losses in 
lumbar spine rather than reducing them. Furthermore, the differences in hind limb seem to be 
independent from changing to new cages, as any intestinal retention of calcium would not be 
measured in this region. Therefore, these changes are thought to be unrelated to the variable of 
coprophagia and more in line with general variation. It is noted that the majority of the 
biochemical assays on serum and urine included samples taken from both the first and revised 
method. However, because changing to new cages likely had no direct effect on the BMC, this 
should also not have affected the mineral physiology.  
 
4.4 intestinal calcium absorption 
45Ca in blood increased during pregnancy in the Cyp27b1 null compared to recovery, suggesting 
that intestinal calcium absorption is upregulated during this time. WT mice had similar levels of 
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intestinal calcium absorption throughout the reproductive period, and there were no differences 
between genotypes at any time point. Contrary to our hypothesis, this suggests that calcitriol is 
not required for upregulation of intestinal calcium absorption during pregnancy. The data do 
raise several questions however, as WT mice did not show the same increase in intestinal 
calcium absorption during pregnancy, and neither genotype maintained an increase post-
weaning.  
 
 A variety of possible reasons may explain these unexpected results. The setting of the 
experiment did not allow for calculation of absolute calcium absorption. The original 
investigators of the oral gavage technique reported both the gavage results and the 45Ca results, 
which were consistent with narrow confidence intervals. 221 Similar to subsequent investigators 
however, we have only reported the blood 45Ca results as the gavage results were too variable 
and therefore uninterpretable. 26,224-226 In this manner, blood 45Ca still provides an estimation of 
both active and passive mechanisms across the entire gastrointestinal tract. As a future direction 
for the project, modifying the gavage protocol to accurately assess the radioactivity in the 
intestines may provide a more direct measure. Additionally, intestinal calcium absorption should 
be different on a 0.47 % calcium diet vs. a normal 1 % calcium diet vs. an enriched 2 % calcium 
“rescue diet”.  It is possible that excess calcium in the diet may be greatly increasing passive 
absorption, which is maintained during all of the three time points measured. As a future 
direction, measurement of the changes in relevant gene expression within the duodenum would 
help to provide further confirmation of the increase in intestinal calcium absorption during 
pregnancy. 
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Lastly, the rise in BMC and marked decline in PTH during pregnancy are independent 
confirmation that calcium delivery through the intestines must have improved during pregnancy, 
as indicated by the rise in 45Ca in blood. Again this implies that calcitriol is not required for 
upregulation of intestinal calcium absorption during pregnancy. 
 
4.5 Confirmation of calcitriol absence in the Cyp27b1 null mouse model 
The aforementioned results all suggest that skeletal mineralization and formation occur 
independently of calcitriol during pregnancy and post-weaning. It was therefore pertinent to this 
research to confirm that calcitriol was in fact absent in our Cyp27b1 null mouse model 
throughout the entire time period of reproduction. Calcitriol had been measured previously by 
our collaborators at McGill who created the mouse model, and in their publication they reported 
“not detectable” levels in the null at both 3 wks and 8 wks of age. 30 That is, they described the 
result as “not detectable” but did not report a numerical value. Calcitriol was also measured in 
the other model by Panda, who similarly reported “undetectable” without stating a numerical 
result. 38 Consequently, what value either of the assays actually yielded is unknown. In this thesis 
work, the detection limit of the EIA kit that we used was 6 pmol/L in humans. Calcitriol levels in 
the Cyp27b1 null mouse at baseline were near the human detection limit with a mean of 12 
pmol/L. This could indicate that 12 pmol/L is the actual limit of detection in mice, and that 
calcitriol is undetectable in our knockout model. Conversely, it could also indicate that a low 
level of calcitriol can be formed despite the absence of Cyp27b1. It is likely that the former is 
correct, because the assay uses mouse antibodies and is designed for assay of human serum; the 
detection limit for mouse serum has not been reported. Therefore, a non-specific increase in the 
apparent limit of detection is likely whenever mouse serum is used in an assay using antibodies 
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raised in mice. It is far less likely that the mice are still making calcitriol despite absence of the 
only gene known to be involved in calcitriol formation; however, the possibility exists as the full 
annotation of gene and protein functions continues in mice and humans. 30,31,56  
 
The level of calcitriol in the Cyp27b1 null is not statistically lower than WT at baseline, although 
it was numerically lower; about one quarter that of WT (12 pmol/L vs. 46 pmol/l). The lack of 
statistical significance is likely due to the enriched diet suppressing expression of calcitriol in the 
basal, non-pregnant state, and due to the low sample size. Previous research found a significant 
difference between the two genotypes at baseline, however these mice were on a diet of regular 
chow and the WT mice had greater levels of calcitriol (150 pmol/L) than found in our study (46 
pmol/L). 30 A larger sample size in our study would likely have helped to differentiate what 
really is a true difference between WT and Cyp27b1 null calcitriol levels at baseline.  
 
4.6 Source of the rise in maternal calcitriol during pregnancy 
Calcitriol normally increases two- to five-fold during pregnancy, and as previously described; a 
persistent belief has been that the placenta is the source. 21,137 Measuring calcitriol was, therefore, 
also critical to elucidate the source of calcitriol during the pregnancy-induced rise, whether it 
came from the fetus and placenta or maternal kidneys. Importantly, the assay indicated that 
calcitriol rose significantly as expected in WT during pregnancy (46 pmol/L to 284 pmol/L) and 
lactation (350 pmol/L), and this increase was absent in Cyp27b1 nulls. This suggests that the 
pregnancy-related increase in calcitriol comes from the maternal kidneys and not the placentas. If 
the placentas were a significant source of calcitriol, then the presence of Cyp27b1+/- placentas 
should have resulted in a large increase in serum calcitriol in the Cyp27b1 null mothers mated to 
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HET males. There was a numerical increase in mean calcitriol of pregnant, null females, in the 
assay from 12 pmol/L to 79 pmol/L that was not statistically significant. This could mean either 
that there was no real change in calcitriol, or that the placentas do contribute a small amount of 
calcitriol to the maternal circulation, but not enough to explain the normal two- to five-fold 
increase in pregnant WT mice. This was not a main endpoint of the study and so we were not 
rigorously testing the idea. Should we wish to confirm this further, the rise in calcitriol during 
pregnancy could be analyzed more fairly by comparing Cyp27b1 null and WT mothers that each 
bore only heterozygous pups, by mating Cyp27b1 null and WT mice to WT and null males, 
respectively. 
 
4.7 FGF23 during pregnancy 
There is minimal research on FGF23 during pregnancy, other than prior studies showing that the 
serum concentration doubles in the mother. 56,140 Our results show that the changes in FGF23 
largely mirror the changes in calcitriol, rather than any fluctuations in serum phosphorus. During 
pregnancy, the WT mice experience a significant rise in FGF23 while this is blunted in Cyp27b1 
nulls. The WT levels decrease at late lactation and recovery 1, however, they still remain 
significantly higher than the FGF23 serum concentrations of the knockout females. This 
confirms that the increase in FGF23 may be largely driven by calcitriol during pregnancy.  
 
4.8 Non-VDR mediated actions of calcitriol 
Our hypothesis stated that calcitriol is required for upregulating intestinal calcium absorption 
during pregnancy and post-weaning, and to enable normal recovery of bone mass post-weaning, 
such that the high calcitriol levels in the Vdr null mice are able to act through non-VDR 
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receptors to have these effects. Contrary to that hypothesis, our results indicated that Cyp27b1 
null mice had significantly improved bone and mineral metabolism during both pregnancy and 
post-weaning despite the deficiency of calcitriol. Serum calcium increased, PTH substantially 
reduced, intestinal calcium absorption increased, and BMC increased during pregnancy. They 
lost a normal amount of bone during lactation (more than normal in the hind limb), but this was 
followed by a normalization of serum calcium, BMC increase, femoral length increase, and 
recovery of bone strength and cortical parameters during post-weaning. Bone mass achieved by 4 
wks of post-weaning actually exceeded the pre-pregnancy value.  These results are largely 
similar to what was seen with loss of the VDR in Vdr null mice. Mice lacking calcitriol’s 
receptor upregulated intestinal calcium absorption, mineralized osteoid, and increased BMC 
during pregnancy, lost a normal amount of bone mass during lactation, and recovered BMC post-
weaning to a value significantly higher than prior to pregnancy. 147 Overall, our data suggest that 
calcitriol was not acting through alternative signalling mechanisms to upregulate bone formation 
in the Vdr null. Instead, the similar phenotypes of Cyp27b1 null and Vdr null mice during the 
reproductive cycles suggest that calcitriol’s actions were lost in both, and that the adaptations to 
pregnancy, lactation, and post-weaning were achievable despite loss of calcitriol’s actions. The 
high serum calcitriol levels observed in the Vdr null females are likely a response to absence of 
the receptor but do not imply retained biological activity of calcitriol in the absence of its 
receptor. Calcitriol is likely not required to regulate intestinal and bone metabolism during 
reproduction, and our results do not support the existence of alternative signalling mechanisms 
for calcitriol action.  
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4.9 Limitations 
Although animal models provide excellent starting points for research, their limitations must be 
recognized with respect to the elementary findings and applications to the etiology of human 
disease. All mammals experience bone loss during lactation followed by a full recovery post-
weaning; however, there are clear differences in their physiological adaptations to pregnancy 
compared with humans. Mice are polytocous whereas humans generally nurse singletons, such 
that there are enhanced skeletal losses and recovery in mice. Rodents therefore upregulate 
intestinal calcium absorption during lactation while humans do not need this mechanism to 
obtain adequate calcium. Comparisons of the recovery process between species may therefore be 
made with caution, and any results require translation and verification in humans. Additionally, it 
may be questioned whether the results found here are specifically due to the loss of calcitriol, or 
whether indirect effects come into play, such as genetic ablation of the Cyp27b1 gene and 
compensation by marked hyperparathyroidism. There were also significant differences in the 
mouse phenotype using the enriched diet as compared to previous research as discussed, which 
could have affected the results. In the future, conditional mouse models of loss of calcitriol 
during post-weaning recovery may be useful for teasing out the specific role of calcitriol during 
this time point. It also would have been useful to analyze the diet and confirm its contents to 
further investigate why it was not adequate to prevent osteomalacia and secondary 
hyperparathyroidism in the Cyp27b1 null mice. However by the time this became apparent, the 
batch of diet had all been consumed.  
 
The enriched diet was necessary for the mice to become pregnant promptly but it confounded the 
situation. WT mice did not show the normal magnitude of excursions in bone mineral content 
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during lactation, particularly that losses during lactation were significantly blunted. Performing 
further DXA measurements using mice placed in clean cages the night prior eliminated the 
influence of coprophagia in artificially raising the late lactation values. These scans were largely 
similar to the initial measurements and suggests that the blunted BMC losses during lactation 
result from the enriched diet. Previous research in the Kovacs laboratory have also shown this 
effect, using PTH WT and null mice in the Black Swiss strain. 140 On a normal diet with 1 % 
calcium, WT and null mice gained BMC during pregnancy, lost during lactation to 15 % to 18 % 
lower than their baseline values, and restored the skeleton above baseline post-weaning. 
However on the enriched diet, the lactational decline was reduced while the gains achieved 
during pregnancy and recovery were unchanged. This indicates that increased availability of 
dietary calcium reduces skeletal resorption during lactation in mice, unlike in women who have 
been shown to lose a similar amount of BMD during lactation regardless of calcium intake. 171 It 
is also noted that DXA does not provide any 3-dimensional information about structure, and so 
the information provided will differ from the 3-dimensional technique of µCT. 
 
Due to the short time period of a Masters degree, it wasn’t possible to repeat experiments when 
trends were discovered that might have been resolved with larger sample sizes. The intestinal 
calcium absorption experiments were performed closer to the end of the project and involved 
numerous attempts at standardizing the protocol. Further experiments here are necessary to 
elucidate the effects on intestinal calcium absorption with greater accuracy, especially by looking 
at lactation. As a result of the short time frame, there are numerous other limitations due to a lack 
of data. µCT of the skeleton during pregnancy was not assessed, such that any changes in 
skeletal microarchitecture between baseline and late lactation are unknown. Furthermore, the 
	  148	  
femur was the only bone assessed for microCT. Analysis of the lumbar vertebrae should also be 
performed. Similarly, time did not permit the analysis of histomorphometry, which would 
provide critical information on trabecular structure. It is possible that the Cyp27b1 null mice had 
significant osteomalacia during the whole experiment, as would have been evident with the 
measurement of osteoid and cell numbers. 
 
4.10 Future considerations 
4.10.1 Calcitriol assay for use in mouse research 
Our EIA kit used to measure calcitriol in the Cyp27b1 null and WT mice yielded a baseline value 
of 12 pmol/L for the null mice, while the limit of detection for human samples was 6 pmol/L. 
Although it is likely that calcitriol is absent in the Cyp27b1 null female mice, we cannot be 
certain based on the sensitivity of the assay. Finding a more sensitive calcitriol assay for use in 
mouse research, such as high performance liquid chromatography, would help to confirm that 
calcitriol is undetectable in the knockout model. 
 
4.10.2 Measurement of calcitriol during pregnancy 
Our results show that calcitriol rose significantly in the WT mothers during pregnancy while this 
rise was absent in the Cyp27b1 nulls, consistent with prior literature showing that calcitriol 
comes from the maternal kidneys during pregnancy with little or no contribution from placentas. 
We cannot, however, completely exclude a contribution from the placenta. The WT mothers 
would have a litter of WT and heterozygous pups, while the null mothers would have a litter of 
null and heterozygous pups, and this could imbalance the potential fetal and placental 
contribution of calcitriol to the maternal circulation. In order to make a proper comparison 
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between mothers and evaluate the placentas as a significant source of calcitriol during 
pregnancy, WT dams should be mated to Cyp27b1 null studs and Cyp27b1 null dams should be 
mated to WT studs. This would allow for all mothers to only have litters with heterozygous pups, 
and any difference between the two genotypes of mice in the levels of calcitriol achieved during 
pregnancy could be attributed to the maternal kidneys rather than the contribution of placentas. A 
further test could involve including Cyp27b1 null dams mated to Cyp27b1 null studs, which 
would mean that all fetuses and placentas would lack that ability to make calcitriol. Comparing 
the calcitriol level of Cyp27b1 null mothers bearing only Cyp27b1 null pups to Cyp27b1 null 
mothers bearing only heterozygous pups would help identify the placental contribution to 
calcitriol in the maternal circulation, if any.  
 
4.10.3 Improvements to study power 
Other laboratory members are currently performing experiments to address the limitations of this 
research due to lack of data. As mentioned, the blood 45Ca values suggest that intestinal calcium 
absorption was upregulated in the Cyp27b1 null during pregnancy, but a larger sample size and 
more direct measure of radioactivity accumulated in the intestine will help to provide 
confirmation. These studies will also be performed during the time period of lactation. Studies 
are also being done now to measure the calcium content of milk. In the future, femur and lumbar 
vertebrae are to be collected at late pregnancy and analyzed by microCT. Once collected, all of 
the vertebral samples will be analyzed by microCT and histomorphometry will also be 
performed. Another experiment to complete will involve intestinal gene expression to assess 
whether intestinal calcium absorption was actually upregulated during pregnancy.  
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4.10.4 Cell culture experiments to identify factors involved in post-weaning recovery 
Our results indicate that calcitriol is not required for the normal recovery of bone mass post-
weaning. This would suggest that other factors are able to regulate mineral and bone metabolism 
during the reproductive cycle. As the known calciotropic hormones have already been 
investigated in the Kovacs laboratory for their role in the recovery phase to no avail, the next 
step would be to broaden the spectrum of search. Genome-wide microarrays on bone and 
marrow during post-weaning may help to identify the differentially regulated genes that 
stimulate recovery following lactation. Cell culture experiments would then be able to narrow the 
list of candidate genes and determine if they stimulate osteoblast proliferation, differentiation, or 
mineralization in vitro. 
 
4.11 Conclusions 
My research hypothesis stated that calcitriol is required for upregulating intestinal calcium 
absorption during pregnancy and post-weaning, and to enable normal recovery of bone mass 
post-weaning, such that the high calcitriol levels in the Vdr null mice are able to act through 
alternative signalling mechanisms to have these effects. However, my studies in Cyp27b1 null 
mice largely refute that hypothesis. During pregnancy and post-weaning, Cyp27b1 null mice 
experienced significant improvements in bone and mineral metabolism, confirming that these 
adaptations to reproduction are achieved independent of calcitriol, or at least in a low calcitriol 
setting, given the limitations of the human-based calcitriol assay. Rather than being involved in 
the recovery phase, calcitriol may still serve a protective role against endocortical resorption 
during lactation, as the Cyp27b1 null mice experienced greater losses of cortical bone during this 
period. The effects on bone during pregnancy and recovery are largely similar to what was seen 
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with loss of the VDR, further confirming that calcitriol was not acting through alternative 
signalling pathways in Vdr null mice, at least for its direct actions to promote deposition of 
skeletal mineral. Nonetheless, before the intestinal calcium absorption experiments are redone 
with adjusted methodology, we cannot completely exclude the possibility of non-VDR mediated 
actions of calcitriol on the intestine.  
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  having	  possession	  of	  and	  the	  right	  to	  reproduce	  the	  Wiley	  Materials	  pursuant	  to	  Section	  2	  herein	  during	  the	  continuance	  of	  this	  Agreement.	  You	  agree	  that	  you	  own	  no	  right,	  title	  or	  interest	  in	  or	  to	  the	  Wiley	  Materials	  or	  any	  of	  the	  intellectual	  property	  rights	  therein.	  You	  shall	  have	  no	  rights	  hereunder	  other	  than	  the	  license	  as	  provided	  for	  above	  in	  Section	  2.	  No	  right,	  license	  or	  interest	  to	  any	  trademark,	  trade	  name,	  service	  mark	  or	  other	  branding	  ("Marks")	  of	  WILEY	  or	  its	  licensors	  is	  granted	  hereunder,	  and	  you	  agree	  that	  you	  shall	  not	  assert	  any	  such	  right,	  license	  or	  interest	  with	  respect	  thereto	  
• NEITHER	  WILEY	  NOR	  ITS	  LICENSORS	  MAKES	  ANY	  WARRANTY	  OR	  REPRESENTATION	  OF	  ANY	  KIND	  TO	  YOU	  OR	  ANY	  THIRD	  PARTY,	  EXPRESS,	  IMPLIED	  OR	  STATUTORY,	  WITH	  RESPECT	  TO	  THE	  MATERIALS	  OR	  THE	  ACCURACY	  OF	  ANY	  INFORMATION	  CONTAINED	  IN	  THE	  MATERIALS,	  INCLUDING,	  WITHOUT	  LIMITATION,	  ANY	  IMPLIED	  WARRANTY	  OF	  MERCHANTABILITY,	  ACCURACY,	  SATISFACTORY	  QUALITY,	  FITNESS	  FOR	  A	  PARTICULAR	  PURPOSE,	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USABILITY,	  INTEGRATION	  OR	  NON-­‐INFRINGEMENT	  AND	  ALL	  SUCH	  WARRANTIES	  ARE	  HEREBY	  EXCLUDED	  BY	  WILEY	  AND	  ITS	  LICENSORS	  AND	  WAIVED	  BY	  YOU.	  	  
• WILEY	  shall	  have	  the	  right	  to	  terminate	  this	  Agreement	  immediately	  upon	  breach	  of	  this	  Agreement	  by	  you.	  
• You	  shall	  indemnify,	  defend	  and	  hold	  harmless	  WILEY,	  its	  Licensors	  and	  their	  respective	  directors,	  officers,	  agents	  and	  employees,	  from	  and	  against	  any	  actual	  or	  threatened	  claims,	  demands,	  causes	  of	  action	  or	  proceedings	  arising	  from	  any	  breach	  of	  this	  Agreement	  by	  you.	  
• IN	  NO	  EVENT	  SHALL	  WILEY	  OR	  ITS	  LICENSORS	  BE	  LIABLE	  TO	  YOU	  OR	  ANY	  OTHER	  PARTY	  OR	  ANY	  OTHER	  PERSON	  OR	  ENTITY	  FOR	  ANY	  SPECIAL,	  CONSEQUENTIAL,	  INCIDENTAL,	  INDIRECT,	  EXEMPLARY	  OR	  PUNITIVE	  DAMAGES,	  HOWEVER	  CAUSED,	  ARISING	  OUT	  OF	  OR	  IN	  CONNECTION	  WITH	  THE	  DOWNLOADING,	  PROVISIONING,	  VIEWING	  OR	  USE	  OF	  THE	  MATERIALS	  REGARDLESS	  OF	  THE	  FORM	  OF	  ACTION,	  WHETHER	  FOR	  BREACH	  OF	  CONTRACT,	  BREACH	  OF	  WARRANTY,	  TORT,	  NEGLIGENCE,	  INFRINGEMENT	  OR	  OTHERWISE	  (INCLUDING,	  WITHOUT	  LIMITATION,	  DAMAGES	  BASED	  ON	  LOSS	  OF	  PROFITS,	  DATA,	  FILES,	  USE,	  BUSINESS	  OPPORTUNITY	  OR	  CLAIMS	  OF	  THIRD	  PARTIES),	  AND	  WHETHER	  OR	  NOT	  THE	  PARTY	  HAS	  BEEN	  ADVISED	  OF	  THE	  POSSIBILITY	  OF	  SUCH	  DAMAGES.	  THIS	  LIMITATION	  SHALL	  APPLY	  NOTWITHSTANDING	  ANY	  FAILURE	  OF	  ESSENTIAL	  PURPOSE	  OF	  ANY	  LIMITED	  REMEDY	  PROVIDED	  HEREIN.	  	  
• Should	  any	  provision	  of	  this	  Agreement	  be	  held	  by	  a	  court	  of	  competent	  jurisdiction	  to	  be	  illegal,	  invalid,	  or	  unenforceable,	  that	  provision	  shall	  be	  deemed	  amended	  to	  achieve	  as	  nearly	  as	  possible	  the	  same	  economic	  effect	  as	  the	  original	  provision,	  and	  the	  legality,	  validity	  and	  enforceability	  of	  the	  remaining	  provisions	  of	  this	  Agreement	  shall	  not	  be	  affected	  or	  impaired	  thereby.	  	  
• The	  failure	  of	  either	  party	  to	  enforce	  any	  term	  or	  condition	  of	  this	  Agreement	  shall	  not	  constitute	  a	  waiver	  of	  either	  party's	  right	  to	  enforce	  each	  and	  every	  term	  and	  condition	  of	  this	  Agreement.	  No	  breach	  under	  this	  agreement	  shall	  be	  deemed	  waived	  or	  excused	  by	  either	  party	  unless	  such	  waiver	  or	  consent	  is	  in	  writing	  signed	  by	  the	  party	  granting	  such	  waiver	  or	  consent.	  The	  waiver	  by	  or	  consent	  of	  a	  party	  to	  a	  breach	  of	  any	  provision	  of	  this	  Agreement	  shall	  not	  operate	  or	  be	  construed	  as	  a	  waiver	  of	  or	  consent	  to	  any	  other	  or	  subsequent	  breach	  by	  such	  other	  party.	  	  
• This	  Agreement	  may	  not	  be	  assigned	  (including	  by	  operation	  of	  law	  or	  otherwise)	  by	  you	  without	  WILEY's	  prior	  written	  consent.	  
• Any	  fee	  required	  for	  this	  permission	  shall	  be	  non-­‐refundable	  after	  thirty	  (30)	  days	  from	  receipt	  by	  the	  CCC.	  
• These	  terms	  and	  conditions	  together	  with	  CCC's	  Billing	  and	  Payment	  terms	  and	  conditions	  (which	  are	  incorporated	  herein)	  form	  the	  entire	  agreement	  between	  you	  and	  WILEY	  concerning	  this	  licensing	  transaction	  and	  (in	  the	  absence	  of	  fraud)	  supersedes	  all	  prior	  agreements	  and	  representations	  of	  the	  parties,	  oral	  or	  written.	  This	  Agreement	  may	  not	  be	  amended	  except	  in	  writing	  signed	  by	  both	  parties.	  This	  Agreement	  shall	  be	  binding	  upon	  and	  inure	  to	  the	  benefit	  of	  the	  parties'	  successors,	  legal	  representatives,	  and	  authorized	  assigns.	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• In	  the	  event	  of	  any	  conflict	  between	  your	  obligations	  established	  by	  these	  terms	  and	  conditions	  and	  those	  established	  by	  CCC's	  Billing	  and	  Payment	  terms	  and	  conditions,	  these	  terms	  and	  conditions	  shall	  prevail.	  
• WILEY	  expressly	  reserves	  all	  rights	  not	  specifically	  granted	  in	  the	  combination	  of	  (i)	  the	  license	  details	  provided	  by	  you	  and	  accepted	  in	  the	  course	  of	  this	  licensing	  transaction,	  (ii)	  these	  terms	  and	  conditions	  and	  (iii)	  CCC's	  Billing	  and	  Payment	  terms	  and	  conditions.	  
• This	  Agreement	  will	  be	  void	  if	  the	  Type	  of	  Use,	  Format,	  Circulation,	  or	  Requestor	  Type	  was	  misrepresented	  during	  the	  licensing	  process.	  
• This	  Agreement	  shall	  be	  governed	  by	  and	  construed	  in	  accordance	  with	  the	  laws	  of	  the	  State	  of	  New	  York,	  USA,	  without	  regards	  to	  such	  state's	  conflict	  of	  law	  rules.	  Any	  legal	  action,	  suit	  or	  proceeding	  arising	  out	  of	  or	  relating	  to	  these	  Terms	  and	  Conditions	  or	  the	  breach	  thereof	  shall	  be	  instituted	  in	  a	  court	  of	  competent	  jurisdiction	  in	  New	  York	  County	  in	  the	  State	  of	  New	  York	  in	  the	  United	  States	  of	  America	  and	  each	  party	  hereby	  consents	  and	  submits	  to	  the	  personal	  jurisdiction	  of	  such	  court,	  waives	  any	  objection	  to	  venue	  in	  such	  court	  and	  consents	  to	  service	  of	  process	  by	  registered	  or	  certified	  mail,	  return	  receipt	  requested,	  at	  the	  last	  known	  address	  of	  such	  party.	  
WILEY OPEN ACCESS TERMS AND CONDITIONS 
Wiley Publishes Open Access Articles in fully Open Access Journals and in Subscription journals offering Online 
Open. Although most of the fully Open Access journals publish open access articles under the terms of the 
Creative Commons Attribution (CC BY) License only, the subscription journals and a few of the Open Access 
Journals offer a choice of Creative Commons Licenses. The license type is clearly identified on the article. 
The Creative Commons Attribution License 
The Creative Commons Attribution License (CC-BY) allows users to copy, distribute and transmit an article, 
adapt the article and make commercial use of the article. The CC-BY license permits commercial and non- 
Creative Commons Attribution Non-Commercial License 
The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits use, distribution and 
reproduction in any medium, provided the original work is properly cited and is not used for commercial 
purposes.(see below) 
Creative Commons Attribution-Non-Commercial-NoDerivs License 
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) permits use, 
distribution and reproduction in any medium, provided the original work is properly cited, is not used for 
commercial purposes and no modifications or adaptations are made. (see below) 
Use by commercial "for-profit" organizations 
Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further explicit 
permission from Wiley and will be subject to a fee. 
Further details can be found on Wiley Online Libraryhttp://olabout.wiley.com/WileyCDA/Section/id-410895.html 	  	  
Other	  Terms	  and	  Conditions:	  	  	  	  
v1.10	  Last	  updated	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Appendix C 
AMERICAN SOCIETY FOR NUTRITION LICENSE 
TERMS AND CONDITIONS 
Oct 25, 2016 
 
 
 
This Agreement between Brittany Gillies ("You") and American Society for Nutrition ("American Society for 
Nutrition") consists of your license details and the terms and conditions provided by American Society for Nutrition 
and Copyright Clearance Center. 
License Number 3976011148388 
License date Oct 25, 2016 
Licensed Content Publisher American Society for Nutrition 
Licensed Content Publication The American Journal of Clinical Nutrition 
Licensed Content Title Overview of general physiologic features 
and functions of vitamin D 
Licensed Content Author Hector F DeLuca 
Licensed Content Date Dec 1, 2004 
Licensed Content Volume 
Number 
80 
Licensed Content Issue 
Number 
6 
Type of Use Thesis/Dissertation 
Requestor type Student 
Portion Figures/table/illustration 
Number of 
Figures/table/illustration 
1 
List of figures/table/ 
illustration 
Figure 6 
Order reference number  
Title of your dissertation / Role of calcitriol in regulating maternal bone 
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thesis and mineral metabolism during pregnancy, 
lactation, and post-weaning recovery 
Expected completion date May 2017 
Estimated size(pages) 180 
Requestor Location Brittany Gillies 
48B Hamilton Avenue 
 
 
St. John's, NL A1E1H7 
Canada 
Attn: Brittany Gillies 
	  
Billing Type Invoice 	  
Billing Address Brittany Gillies 
48B Hamilton Avenue 
 
 
St. John's, NL A1E1H7 
Canada 
Attn: Brittany Gillies 
	  
Total 0.00 CAD 	  
Terms and Conditions 	  
_ 
Terms and Conditions for RightsLink Licenses 
1) This license agreement ("Agreement") is between the Customer as identified by the user 
in RightsLink ("Customer") and The American Society for Nutrition, Inc, a nonprofit corporation with offices at 
9211 Corporate Blvd., Suite 300, Rockville, MD 20850 USA ("ASN"), regarding content published in one of the 
following ASN journals: The American Journal of Clinical Nutrition (AJCN) or The Journal of Nutrition (JN) or 
Advances in Nutrition. The license administrator for this Agreement is the Copyright Clearance Center (CCC). 
2) Introduction 
The publisher of this copyrighted material is ASN. By clicking "accept" in connection with completing this 
licensing transaction, you agree that the following terms and conditions apply to this transaction (along with the 
Billing and Payment terms and conditions established by CCC, at the time that you opened 
your RightsLink account and that are available at any time at http://myaccount.copyright.com. 
3) ASN occasionally publishes material for which it does not hold copyright; in such instances, ASN identifies and 
properly cites the appropriate copyright holder. It is the Customer’s responsibility to verify that ASN holds 
copyright for which the Customer is requesting permission. If the material is credited to another source, then ASN 
does not have the authority to grant permission for its reuse and this license is to be considered invalid. 
4) Limited License 
ASN hereby grants to you a non-exclusive license to use this material. Licenses are for one-time use only with a 
maximum distribution equal to the number that you identified in the licensing process. Except when material is 
licensed for reuse in a scholarly journal, magazine, newsletter, newspaper, book, or textbook, in which case 
permission extends to reprints of the product produced for publisher restocking, any form of republication must be 
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completed within one year from the date hereof (although copies prepared before then may be distributed 
thereafter). Reprints must not be new products nor marketed as such: reuse in new volumes or new editions must 
be licensed explicitly. Any form of republication must be completed within one year from the date hereof (although 
copies prepared before then may be distributed thereafter); and any electronic posting is limited to the time specified 
in this request, if any. ASN asks that commercial organizations limit distribution of photocopies to within the 
organization requesting permission. Requests to distribute content copyrighted by ASN outside of the requesting 
organization should be processed as reprints or ePrints. Use of more than 50% of an article copyrighted by ASN in a 
single new work must be reviewed separately by ASN staff. 
5) Geographic Rights 
Licenses may be exercised solely in the country or countries specified by the Customer on the Quick Price or 
Additional Data page in RightsLink. However, in cases in which ASN has exclusive republication licensees in 
specific countries, licenses to reproduce full-text material in these countries may be revoked by ASN. In such cases, 
the Customer would be referred to the license agent in the respective country or countries. For questions about 
whether this would apply to your order, please contact ASN at publications@nutrition.org. 
6) Alterations/Modifications 
Except for adaptations of tables and figures and for translations of content as described below, material may not be 
modified. Translations of figures, tables, and excerpts are permitted as transactions within RightsLink. Translations 
of full-text materials must be approved by ASN before the Customer can proceed with the RightsLink transaction. 
Full-text translation requests processed through CCC will be considered invalid unless the Customer enters the 
ASN-issued approval code for the translation. A copy of all full-text translations must be sent to ASN. 
7) Reservation of Rights 
ASN reserves all rights not specifically granted in the combination of (i) the license details provided by you and 
accepted in the course of this licensing transaction, (ii) these terms and conditions, and (iii) CCC's Billing and 
Payment terms and conditions. 
8) License Contingent on Payment 
While you may exercise the rights licensed immediately upon issuance of the license at the end of the licensing 
process for the transaction, provided that you have disclosed complete and accurate details of your proposed use, no 
license is finally effective unless and until full payment is received from you (either by ASN or by CCC) as 
provided in CCC's Billing and Payment terms and conditions. If full payment is not received on a timely basis, then 
any license preliminarily granted shall be deemed automatically revoked and shall be void as if never granted. 
Further, in the event that you breach any of these terms and conditions or any of CCC's Billing and Payment terms 
and conditions, the license is automatically revoked and shall be void as if never granted. Use of materials as 
described in a revoked license, as well as any use of the materials beyond the scope of an unrevoked license, may 
constitute copyright infringement and publisher reserves the right to take any and all action to protect its copyright 
in the materials. 
9) Copyright Notice: Disclaimer 
You must give complete credit to the original source in connection with any reproduction or adaptation of the 
licensed material: 'Am J Clin Nutr (year;volume:page range), American Society for Nutrition,' or 'J Nutr 
(year;volume:page range), American Society for Nutrition;.'Adv Nutr (year;volume:page range), American Society 
for Nutrition.'For translations: Figures or tables cannot be used in advertisements. 
Full-text translations of articles published in The Journal of Nutrition must include the following 
disclaimer: Translated from the original into LANGUAGE by TRANSLATOR'S NAME. The translator assumes 
responsibility for the accuracy of the translation. The American Society for Nutrition is not responsible for 
translation errors. Readers are encouraged to access the original publication at http://jn.nutrition.org.For 
photocopies and in-house reprints: 
The article will be reprinted in its entirety without change. 
No material will be attached to the reprints, and the reprint will be used for educational purposes only, not to 
promote, sell, or in any way endorse a product. 
The citation appearing on the first page of the article must appear in the reprints. 
As a courtesy, please notify the author of your intended reuse of his or her content. 
All reprints must have reprinted on each:The American Society for Nutrition, Inc., does not endorse any commercial 
enterprise. 
10) Warranties 
ASN makes no representations or warranties with respect to the licensed material. 
11) Indemnity 
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You hereby indemnify and agree to hold harmless ASN and CCC, and their respective officers, directors, 
employees, and agents, from and against any and all claims arising out of your use of the licensed material other 
than as specifically authorized pursuant to this license. 
12) No Transfer of License 
This license is personal to you, but may be assigned or transferred by you to a business associate (or to your 
employer) if you give prompt written notice of the assignment or transfer to ASN. No such assignment or transfer 
shall relieve you of the obligation to pay the designated license fee on a timely basis (although payment by the 
identified assignee can fulfill your obligation). 
13) No Amendment Except in Writing 
This license may not be amended except in a writing signed by both parties (or, in the case of ASN, by CCC on 
ASN’s behalf). 
14) Objection to Contrary Terms 
ASN hereby objects to any terms contained in any purchase order, acknowledgment, check endorsement or other 
writing prepared by you, which terms are inconsistent with these terms and conditions or CCC's Billing and 
Payment terms and conditions. These terms and conditions, together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein), comprise the entire agreement between you and ASN (and CCC) 
concerning this licensing transaction. In the event of any conflict between your obligations established by these 
terms and conditions and those established by CCC's Billing and Payment terms and conditions, these terms and 
conditions shall control. 
15) Jurisdiction 
This license Agreement contains the entire understanding of the parties with respect to the licensed content and can 
be modified only by a signed, written agreement. This Agreement shall be construed in accordance with the laws of 
the State of Maryland and the US copyright laws. If any term of this Agreement shall be found invalid by any court 
of competent jurisdiction, such provision shall be enforced to the fullest extent that it is valid and enforceable under 
applicable law, and all other provisions of this Agreement shall remain in full force and effect. For state and local 
governments, the Terms and Conditions do not apply when in conflict with existing statues. 
16) Other  
There are additional terms and conditions, established by Copyright Clearance Center, Inc. ("CCC") as the 
administrator of this licensing service that relate to billing and payment for licenses provided through this service. 
Those terms and conditions apply to each transaction as if they were restated here. As a user of this service, you 
agreed to those terms and conditions at the time that you established your account, and you may see them again at 
any time at http://myaccount.copyright.com. 
Terms and Conditions for Content Services 
 
Subject to these terms of use, any terms set forth on the particular order, and payment of the applicable fee, you may 
make the following uses of the ordered materials: 
 
Content Rental: You may access and view a single electronic copy of the materials ordered for the time period 
designated at the time the order is placed. Access to the materials will be provided through a dedicated content 
viewer or other portal, and access will be discontinued upon expiration of the designated time period. An order for 
Content Rental does not include any rights to print, download, save, create additional copies, to distribute or to 
reuse in any way the full text or parts of the materials. 
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